Surena F. Matin, M.D.

Peer-Reviewed Articles

1. Linehan J, Gottlieb J, Woldu SL, Labbate C, Rose K, Sexton W, Kaimakliotis H, Jacob J, Dickstein R, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y, Murray KS. Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes. Eur Urol Focus 9(6):1052-1058, 2023. e-Pub 2023. PMID: 37263827.
2. Kaimakliotis HZ, Tachibana I, Woldu S, Labbate C, Jacob J, Murray K, Rose K, Sexton W, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipour S, Quek M, O'Donnell M, Eisner BH, Matin SF, Lotan Y, Feldman AS. The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma. Urol Oncol 41(9):387.e1-387.e7, 2023. e-Pub 2023. PMID: 37246135.
3. Rose KM, Murray KS, Labbate C, Woldu S, Linehan J, Jacob J, Kaimakliotis H, Dickstein R, Feldman A, Matin SF, Lotan Y, Humphreys MR, Sexton WJ. Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease. Eur Urol Focus 9(5):807-812, 2023. e-Pub 2023. PMID: 37059620.
4. Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM, Psutka SP, Raman JD, Smith AB, Smith L. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. J Urol 209(6):1071-1081, 2023. e-Pub 2023. PMID: 37096584.
5. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
6. Labbate C, Woldu S, Murray K, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin M, Humphreys M, Ghodoussipor S, Quek M, O'Donnell M, Eisner B, Feldman A, Lotan Y, Matin SF. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. J Urol 209(5):872-881, 2023. e-Pub 2023. PMID: 36657029.
7. Woldu SL, Labbate C, Murray KS, Rose K, Sexton W, Tachibana I, Kaimakliotis H, Jacob J, Dickstein R, Linehan J, Nieder A, Bjurlin MA, Humphreys M, Ghodoussipour S, Quek ML, O'Donnell M, Eisner BH, Feldman AS, Matin SF, Lotan Y. Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes. Urol Oncol 41(3):147.e15-147.e21, 2023. e-Pub 2022. PMID: 36424224.
8. Lange S, Calleris G, Matin SF, Rouprêt M. Optimizing Lymph Node Dissection at the Time of Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. Eur Urol Focus 9(2):280-282, 2023. e-Pub 2023. PMID: 36642620.
9. Mertens LS, Sharma V, Matin SF, Boorjian SA, Houston Thompson R, van Rhijn BWG, Masson-Lecomte A. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies. Eur Urol Open Sci 49:60-66, 2023. e-Pub 2023. PMID: 36793750.
10. Lange SM, Matin SF. EDITORIAL COMMENT. Urology 172:155-156, 2023. PMID: 36773986.
11. Abdelsalam ME, Awad A, Baiomy A, Irwin D, Karam JA, Matin SF, Sheth RA, Habibollahi P, Odisio BC, Lu T, Ahrar K. Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765867.
12. Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
13. Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SF. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. e-Pub 2022. PMID: 35961847.
14. Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS, Haas NB. Adjuvant therapy in patients with sarcomatoid RCC: Post hoc analysis from ECOG-ACRIN E2805. BJU Int 129(6):718-722, 2022. e-Pub 2021. PMID: 34480522.
15. Westerman ME, Yevich SM, Dori Y, Ward JF, Pisters LL, Karam JA, Wood CG, Avritscher R, Matin SF. Lymphangioembolization for iatrogenic chylous ascites after retroperitoneal urologic surgery. BJU Int 129(5):585-587, 2022. e-Pub 2022. PMID: 34962705.
16. Pieretti AC, Ozambela M, Westerman ME, Nogueras-Gonzalez GM, Segarra LA, Zacharias NM, Vaporciyan A, Hofstetter W, Huynh T, Aldousari S, Matin SF, Karam JA. Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus. Clin Genitourin Cancer. e-Pub 2022. PMID: 35279419.
17. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2021. PMID: 35475152.
18. Pieretti AC, Shapiro DD, Westerman ME, Hwang H, Wang X, Segarra LA, Campbell MT, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39(12):837.e9-837.e17, 2021. e-Pub 2021. PMID: 34551888.
19. Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol:101097JU0000000000002350. e-Pub 2021. PMID: 34915741.
20. Adibi M, McCormick B, Economides MP, Petros F, Xiao L, Guo C, Shah A, Kamat AM, Dinney C, Navai N, Gao J, Siefker-Radtke A, Matin SF, Campbell MT. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. e-Pub 2021. PMID: 35039231.
21. Pieretti AC, Westerman ME, Childs A, Millward N, Shapiro DD, Sircar K, Rao P, Jonasch E, Campbell MT, Tannir NM, Matin SF, Wood CG, Karam JA. Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urol Oncol 39(11):790.e17-790.e23, 2021. e-Pub 2021. PMID: 34301458.
22. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
23. Ghandour RA, Freifeld Y, Cheaib J, Singla N, Meng X, Kenigsberg A, Bagrodia A, Woldu S, Hoffman-Censits J, Enikeev D, Rapoport L, Petros FG, Raman JD, Pierorazio PM, Matin SF, Margulis V. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Urol Oncol 39(11):788.e15-788.e21, 2021. e-Pub 2021. PMID: 34330655.
24. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke A, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma. BJUI Compass. e-Pub 2021.
25. Altok M, Chapin BF, Matin SF, Achim MF, Gregg JR, Davis JW. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase. Urology 155:144-151, 2021. e-Pub 2021. PMID: 33676955.
26. Miest T, Khanna A, Sharma V, Hensley PJ, Campbell R, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Potretzke A, Matin SF, Murthy PB, Haber GP, Lee B, Boorjian SA. Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma Following Radical Cystectomy. J Urol:101097JU0000000000002211. e-Pub 2021. PMID: 34547921.
27. Pisters PW, Ranasinghe W, Wei W, Wood CG, Matin SF, Ward JF, Pisters LL. Long-term renal functional outcomes following ureteroureterostomy performed during multi-organ resection for non-urothelial cancers. BJUI Compass 2(5):348-354, 2021. e-Pub 2021. PMID: 35474874.
28. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. e-Pub 2021. PMID: 34228889.
29. Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffeille V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. Eur Urol. e-Pub 2021. PMID: 34023164.
30. McIntosh AG, Umbreit EC, Wood CG, Matin SF, Karam JA. Role of lymph node dissection at the time of open or minimally invasive nephroureterectomy. Transl Androl Urol 10(5):2233-2245, 2021. PMID: 34159106.
31. Abdelsalam ME, Sabir SH, Ba SBK, Karam JA, Matin SF, Wood CG, Ahrar K. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies. AJR Am J Roentgenol:1-7. e-Pub 2021. PMID: 33909469.
32. Sharma V, Miest TS, Juvet TS, Toussi A, Packiam V, Chamie K, Matin SF, Boorjian SA, Thompson RH, Frank I, Tollefson MK, Potretzke AM. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated meta-Analysis. J Urol:101097JU0000000000001834. e-Pub 2021. PMID: 33908802.
33. Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney C, McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper-Tract and Bladder Urothelial Carcinoma. J Urol:101097JU0000000000001788. e-Pub 2021. PMID: 33881933.
34. Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffeille V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. Eur Urol Focus. e-Pub 2021. PMID: 33773965.
35. Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer. BJU Int. e-Pub 2021. PMID: 33484074.
36. Sfakianos JP, Gul Z, Shariat SF, Matin SF, Daneshmand S, Plimack E, Lerner S, Roupret M, Pal S. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. Eur Urol Oncol. e-Pub 2020. PMID: 33386276.
37. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. e-Pub 2020. PMID: 33187886.
38. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. e-Pub 2020. PMID: 33046869.
39. McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer 126(17):3950-3960, 2020. e-Pub 2020. PMID: 32515845.
40. Freifeld Y, Ghandour R, Singla N, Woldu S, Bagrodia A, Lotan Y, Rapoport LM, Gazimiev M, Delafuente K, Kulangara R, Robyak H, Petros FG, Raman JD, Matin SF, Margulis V. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urol Oncol 38(9):737.e11-737.e16, 2020. e-Pub 2020. PMID: 32641241.
41. Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupret M, Sfakianos JP, Shariat SF, Faltas BM. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. Eur Urol 78(2):209-220, 2020. e-Pub 2020. PMID: 32571725.
42. Geiger S, Kocher N, Illinsky D, Xylinas E, Chang P, Dewey L, Wagner AA, Petros F, Matin SF, Tobert C, Tracy C, Patard PM, Roumiguie M, Monteiro LL, Kassouf W, Raman JD. Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. Transl Androl Urol 9(4):1780-1785, 2020. PMID: 32944540.
43. Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF, UTUC Collaboration. Efficacy of Preoperative Chemotherapy in High-Risk Upper Tract Urothelial Carcinoma (UTUC). J Urol 203(6):1101-1108, 2020. e-Pub 2020. PMID: 31898919.
44. Loloi J, Shingleton WB, Nakada SY, Zagoria RJ, Landman J, Lee BR, Matin SF, Ahrar K, Leveillee RJ, Cadeddu JA, Raman JD. Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors. J Kidney Cancer VHL 7(2):1-5, 2020. e-Pub 2020. PMID: 32665886.
45. Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Adibi M, Amin MB, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner SP. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol 21(6):776-785, 2020. e-Pub 2020. PMID: 32631491.
46. Singla N, Christie A, Freifeld Y, Ghandour RA, Woldu SL, Clinton TN, Petros FG, Robyak H, Yeh HC, Fang D, Enikeev D, Bagrodia A, Sagalowsky AI, Lotan Y, Raman JD, Matin SF, Margulis V. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urol Oncol. e-Pub 2020. PMID: 32430254.
47. Grant SR, Lei X, Hess KR, Smith GL, Matin SF, Wood CG, Nguyen Q, Frank SJ, Anscher MS, Smith BD, Karam JA, Tang C. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Adv Radiat Oncol 5(3):495-502, 2020. e-Pub 2020. PMID: 32529146.
48. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J, Collaborators. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol 203(4):101097JU0000000000000644, 2020. e-Pub 2019. PMID: 31702432.
49. Geynisman DM, Kadow BT, Shuch BM, Boorjian SA, Matin SF, Rampersaud E, Milestone BN, Plimack ER, Zibelman MR, Kutikov A, Smaldone MC, Chen DY, Viterbo R, Joshi S, Greenberg RE, Malizzia L, McGowan T, Ross EA, Uzzo RG. Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial. J Urol:101097JU0000000000001065. e-Pub 2020. PMID: 32250730.
50. Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol 32(11):1698-1707, 2019. e-Pub 2019. PMID: 31231128.
51. Borregales LD, Adibi M, Thomas AZ, Reis RB, Chery LJ, Devine CE, Wang X, Potretzke AM, Potretzke T, Figenshau RS, Bauman TM, Aboshady YI, Abel EJ, Matin SF, Karam JA, Wood CG. Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy. Eur Urol Focus. e-Pub 2019. PMID: 31685445.
52. Freifeld Y, Ghandour R, Singla N, Woldu S, Clinton T, Kulangara R, Bagrodia A, Matin SF, Petros FG, Raman JD, Robyak H, Yan J, Zhu H, Rapoport L, Lotan Y, Margulis V. Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. Urol Oncol. e-Pub 2019. PMID: 31378586.
53. Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, Shariat SF, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 10(1):2977, 2019. e-Pub 2019. PMID: 31278255.
54. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol 37(6):354.e19-354.e26, 2019. e-Pub 2019. PMID: 30777393.
55. Altok M, Troncoso P, Achim MF, Matin SF, Gonzalez GN, Davis JW. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates. Asian J Androl. e-Pub 2019. PMID: 31115364.
56. Petros FG, Qiao W, Singla N, Clinton TN, Robyak H, Raman JD, Margulis V, Matin SF. Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. Urol Oncol 37(4):292.e1-292.e9, 2019. e-Pub 2018. PMID: 30584035.
57. Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF. Conditional Survival of Patients with Small Renal Masses Undergoing Active Surveillance. BJU Int 123(3):447-455, 2019. e-Pub 2018. PMID: 30007044.
58. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
59. Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, Robichaux CC, Villarreal MF, Weldon JA, Woodson AH, Pilie PG, Fuller GN, Waguespack SG, Matin SF. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol 19(10):1351-1359, 2018. e-Pub 2018. PMID: 30236511.
60. Yu KJ, Keskin SK, Meissner MA, Petros FG, Wang X, Borregales LD, Gu C, Tamboli P, Matin SF, Wood CG, Karam JA. Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging. Cancer 124(20):4023-4031, 2018. e-Pub 2018. PMID: 30276798.
61. Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus. e-Pub 2018. PMID: 30206003.
62. Farnum JA, Vikram R, Rao A, Bedi D, Dinney CP, Matin SF. Accuracy of High-Frequency Endoluminal Ultrasonography for Clinical Staging of Upper Tract Urothelial Carcinoma. J Endourol 32(9):806-811, 2018. e-Pub 2018. PMID: 30014707.
63. Altok M, Babaian K, Achim MF, Achim GC, Troncoso P, Matin SF, Chapin BF, Davis JW. Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection. BJU Int 122(1):66-75, 2018. e-Pub 2018. PMID: 29446205.
64. Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience. World J Urol 36(7):1093-1101, 2018. e-Pub 2018. PMID: 29488096.
65. Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology 116:114-119, 2018. e-Pub 2018. PMID: 29578041.
66. Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis 39(6):752-757, 2018. e-Pub 2018. PMID: 29635281.
67. Pilié P, Hasanov E, Matin SF, Woodson AHH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget 9(34):23390-23395, 2018. e-Pub 2018. PMID: 29805741.
68. Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V. The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology 115:119-124, 2018. e-Pub 2018. PMID: 29499258.
69. Leal I, Milbury K, Engebretson J, Matin SF, Jonasch E, Tannir N, Wood CG, Cohen L. Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliat Support Care 16(2):1-9, 2018. e-Pub 2017. PMID: 28262086.
70. Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE. Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results from a Multicenter Collaboration. Clin Genitourin Cancer 16(2):e443-e450, 2018. e-Pub 2017. PMID: 29113770.
71. Mir MC, Matin SF, Bex A, Spiess PE, Thompson RH, Grob B, van Poppel H. The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urol Nefrol 70(2):109-125, 2018. e-Pub 2018. PMID: 29381020.
72. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121(4):540-548, 2018. e-Pub 2017. PMID: 28941030.
73. Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA. Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses. J Urol 199(2):393-400, 2018. e-Pub 2017. PMID: 28941919.
74. Altok M, Achim MF, Matin SF, Pettaway CA, Chapin BF, Davis JW. A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol 36(1):13.e19-13.e25, 2018. e-Pub 2017. PMID: 28964658.
75. Metcalfe MJ, Petros FG, Rao P, Mork ME, Xiao L, Broaddus RR, Matin SF. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol 199(1):60-65, 2018. e-Pub 2017. PMID: 28797715.
76. Bednarski BK, Slack RS, Katz M, You YN, Papadopolous J, Rodriguez-Bigas MA, Skibber JM, Matin SF, Chang GJ. Assessment of Ileostomy Output Using Telemedicine: A Feasibility Trial. Dis Colon Rectum 61(1):77-83, 2018. PMID: 29215474.
77. Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int 120(6):782-792, 2017. e-Pub 2016. PMID: 27860149.
78. Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 72(4):641-649, 2017. e-Pub 2017. PMID: 28601352.
79. Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X. Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma. Carcinogenesis 38(11):1129-1135, 2017. PMID: 28968893.
80. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, Rathmell WK, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Res 77(19):5313-5326, 2017. e-Pub 2017. PMID: 28807937.
81. Milbury K, Lopez G, Spelman A, Wood C, Matin SF, Tannir NM, Jonasch E, Pisters L, Wei Q, Cohen L. Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psychooncology 26(9):1361-1368, 2017. e-Pub 2016. PMID: 27145447.
82. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies Over Three Decades: Comparison Between the Cytokine (1987-2005) and the Targeted Therapy (2006-2015) Eras. J Urol 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
83. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin SF, Karam JA, Wood CG, Wu X. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with non-metastatic renal cell carcinoma. Cancer 123(18):3617-3627, 2017. e-Pub 2017. PMID: 28543182.
84. Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. J Endourol 31(9):946-953, 2017. e-Pub 2017. PMID: 28731777.
85. Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy Renal Cell Carcinoma Patients with Venous Tumor Thrombus. J Urol 198(2):281-288, 2017. e-Pub 2017. PMID: 28268170.
86. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients with Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer 15(3):363-370, 2017. e-Pub 2017. PMID: 28216278.
87. Pini G, Matin SF, Suardi N, Desai M, Gill I, Porter J, Stein RJ, Sotelo R, Gaboardi F, Porpiglia F. Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal. Minerva Urol Nefrol 69(1):38-55, 2017. e-Pub 2016. PMID: 28009144.
88. Gupta N, Patel A, Ensor J, Ahrar K, Ahrar J, Tam A, Odisio B, Huang S, Murthy R, Mahvash A, Avritscher R, McRae S, Sabir S, Wallace M, Matin SF, Gupta S. Multiple Renal Artery Pseudoaneurysms in Patients Undergoing Renal Artery Embolization Following Partial Nephrectomy: Correlation with RENAL Nephrometry Scores. Cardiovasc Intervent Radiol 40(2):202-209, 2017. e-Pub 2016. PMID: 27681271.
89. Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer 116(1):77-84, 2017. e-Pub 2016. PMID: 27907930.
90. Pini G, Matin SF, Suardi N, Desai M, Gill I, Porter J, Stein RJ, Sotelo R, Gaboardi F, Porpiglia F. Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal. A systematic review. Minerva Urol Nefrol. e-Pub 2016. PMID: 27824248.
91. Thomas AZ, Adibi M, Slack RS, Borregales LD, Merrill MM, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. J Urol 196(3):678-84, 2016. e-Pub 2016. PMID: 27036304.
92. Redrow GP, Matin SF. Upper tract urothelial carcinoma: epidemiology, high risk populations and detection. Minerva Urol Nefrol 68(4):350-8, 2016. e-Pub 2016. PMID: 27008468.
93. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favorable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 2016. e-Pub 2015. PMID: 26059275.
94. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117(5):761-5, 2016. e-Pub 2015. PMID: 26032863.
95. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, Wood CG, Karam JA. Metastases to the Kidney: A Comprehensive Analysis of 151 Patients from a Tertiary Referral Center. BJU Int 117(5):775-82, 2016. e-Pub 2015. PMID: 26053895.
96. Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, Tamboli P, Sircar K, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol 34(5):237.e19-26, 2016. e-Pub 2015. PMID: 26707613.
97. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin SF, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008-16, 2016. e-Pub 2016. PMID: 26969090.
98. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-62, 2016. e-Pub 2015. PMID: 26343003.
99. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35(21):2687-97, 2016. e-Pub 2015. PMID: 26364599.
100. Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol 69(5):866-74, 2016. e-Pub 2015. PMID: 26626617.
101. Katz MH, Slack R, Bruno M, McMillan J, Fleming JB, Lee JE, Bednarski B, Papadopoulos J, Matin SF. Outpatient virtual clinical encounters after complex surgery for cancer: a prospective pilot study of "TeleDischarge". J Surg Res 202(1):196-203, 2016. e-Pub 2016. PMID: 27083967.
102. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer 14(2):130-8, 2016. e-Pub 2015. PMID: 26558524.
103. Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X. Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. Clin Cancer Res 22(8):2074-82, 2016. e-Pub 2015. PMID: 26655847.
104. Zargar H, Atwell TD, Cadeddu JA, de la Rosette JJ, Janetschek G, Kaouk JH, Matin SF, Polascik TJ, Zargar-Shoshtari K, Thompson RH. Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results. Eur Urol 69(1):116-28, 2016. e-Pub 2015. PMID: 25819723.
105. Melquist JJ, Redrow G, Delacroix S, Park A, Faria EE, Karam JA, Matin SF. Comparison of Single-Docking Robotic-Assisted and Traditional Laparoscopy for Retroperitoneal Lymph Node Dissection during Nephroureterectomy with Bladder Cuff Excision for Upper-Tract Urothelial Carcinoma. Urology 87:216-23, 2016. e-Pub 2015. PMID: 26494291.
106. Melkonian SC, Daniel CR, Ye Y, Tannir NM, Karam JA, Matin SF, Wood CG, Wu X. Gene-environment interaction of genome-wide association study-identified susceptibility loci and meat-cooking mutagens in the etiology of renal cell carcinoma. Cancer 122(1):108-15, 2016. e-Pub 2015. PMID: 26551148.
107. Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol 33(12):528-37, 2015. e-Pub 2015. PMID: 26546481.
108. Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, Karam JA. Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney: A Detailed Study of Radiologic, Pathologic and Clinical Outcomes. BJU Int 116(1):85-92, 2015. e-Pub 2015. PMID: 25395040.
109. Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF. Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. Urology 86(1):10-5, 2015. e-Pub 2015. PMID: 26048432.
110. Mork M, Hubosky SG, Rouprêt M, Margulis V, Raman J, Lotan Y, O'Brien T, You N, Shariat SF, Matin SF. Lynch Syndrome: A Primer for Urologists and Panel Recommendations. J Urol 194(1):21-9, 2015. e-Pub 2015. PMID: 25711197.
111. Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma. Minerva Urol Nefrol 67(2):149-56, 2015. e-Pub 2015. PMID: 25645343.
112. Matin SF, Sfakianos JP, Espiritu PN, Coleman JA, Spiess PE. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol. e-Pub 2015. PMID: 26094807.
113. Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, Sircar K, Murugan P, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. e-Pub 2015. PMID: 26004164.
114. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res. e-Pub 2015. PMID: 26014097.
115. Hamdi A, Mulanovich VE, Matin SF, Landon G, Sircar K, Tu SM, Nieto Y. Isolated Renal Mucormycosis in a Transplantation Recipient. J Clin Oncol 33(10):e50-1, 2015. e-Pub 2014. PMID: 24821884.
116. Huang SY, Ahrar K, Gupta S, Wallace MJ, Ensor JE, Krishnamurthy S, Matin SF. Safety and Diagnostic Accuracy of Percutaneous Biopsy in Upper Tract Urothelial Carcinoma. BJU Int 115(4):625-32, 2015. e-Pub 2014. PMID: 24905868.
117. Babaian KN, Kim DY, Kenney PA, Wood CG, Wong J, Sanchez C, Fang JE, Gerber JA, Didic A, Wahab A, Golla V, Torres C, Tamboli P, Qiao W, Matin SF, Wood CG, Karam JA. Preoperative Predictors of Pathological Lymph Node Metastasis in Patients with Renal Cell Carcinoma Undergoing Retroperitoneal Lymph Node Dissection. J Urol 193(4):1101-7, 2015. e-Pub 2014. PMID: 25390078.
118. Merrill MM, Wood CG, Tannir NM, Slack RS, Babaian KN, Jonasch E, Pagliaro LC, Compton Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urol Oncol 33(4):166.e21-9, 2015. e-Pub 2015. PMID: 25700975.
119. Eggener SE, Clark MA, Shikanov S, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Harel M, Cambio J, Shalhav AL, Raman JD. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol 33(3):351-7, 2015. e-Pub 2014. PMID: 24817142.
120. Thomas AZ, Adibi M, Borregales LD, Hoang LN, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol. e-Pub 2015. PMID: 25758610.
121. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol 33(2):53-64, 2015. e-Pub 2014. PMID: 25065704.
122. Melkonian SC, Wang X, Gu J, Matin SF, Tannir NM, Wood CG, Wu X. Mitochondrial DNA Copy Number in Peripheral Blood Leukocytes and the Risk of Clear Cell Renal Cell Carcinoma. Carcinogenesis 36(2):249-55, 2015. e-Pub 2014. PMID: 25524925.
123. Thekdi SM, Milbury K, Spelman A, Wei Q, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Cohen L. Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psychooncology. e-Pub 2015. PMID: 25690556.
124. Karam JA, Wood CG, Compton ZR, Rao P, Vikram R, Ahrar K, Matin SF. Salvage Surgery After Energy Ablation for Renal Masses. BJU Int 115(1):74-80, 2015. e-Pub 2014. PMID: 24656119.
125. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol 142(6):864-71, 2014. PMID: 25389341.
126. Choi H, Underwood M, Boonsirikamchai P, Matin SF, Troncoso P, Ma J. Technical challenges in 3 T magnetic resonance spectroscopic imaging of the prostate-A single-institution experience. Quant Imaging Med Surg 4(4):251-8, 2014. PMID: 25202660.
127. Babaian KN, Merrill MM, Matin SF, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma. J Urol 192:36-42, 2014.
128. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794-9, 2014. e-Pub 2014. PMID: 24633966.
129. Kharadjian TB, Matin SF, Pettaway CA. Early experience of robotic-assisted inguinal lymphadenectomy: review of surgical outcomes relative to alternative approaches. Curr Urol Rep 15(6):412, 2014. PMID: 24756453.
130. Rao P, Monzon F, Jonasch E, Matin SF, Tamboli P. Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome-clinicopathological features and comparative genomic analysis of 3 cases. Hum Pathol. e-Pub 2014. PMID: 25081542.
131. Matin SF, Shariat SF, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, Grollman AP. Highlights from the first symposium on upper tract urothelial carcinoma. Urol Oncol 32(3):309-16, 2014. e-Pub 2014. PMID: 24397995.
132. Milbury K, Spelman A, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Wei Q, Cohen L. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol 32(7):663-70, 2014. e-Pub 2014. PMID: 24470003.
133. Faria EF, Caputo PA, Wood CG, Karam JA, Nogueras-González GM, Matin SF. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol 32(1):265-71, 2014. e-Pub 2013. PMID: 23783881.
134. Faria E, Turturro F, Rao P, Matin SF. Malignant Epithelioid Angiomyolipoma: Tumor and Metabolic Response to Everolimus as Evaluated with Positron Emission Tomography. Clin Genitourin Cancer 11(4):e1-5, 2013. e-Pub 2013. PMID: 23791549.
135. Chen XP, Xiong GY, Li XS, Matin SF, Garcia M, Fang D, Wang TY, Yu W, Gong K, Song Y, He ZS, He Q, Zhou LQ. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 112(7):917-24, 2013. e-Pub 2013. PMID: 23905945.
136. Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol 39(6):817-22, 2013. PMID: 24456786.
137. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. Eur Urol 63(6):1122-1127, 2013. e-Pub 2013. PMID: 23419322.
138. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int 111(7):1068-74, 2013. e-Pub 2013. PMID: 23551693.
139. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int 111(6):997-1005, 2013. e-Pub 2013. PMID: 23510233.
140. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189(4):1214-21, 2013. e-Pub 2012. PMID: 23023150.
141. Andino L, Davis JW, Wei W, Prokhorova, IN, Troncoso P, Matin SF. Correlation of histomorphologic findings and partial neurovascular bundle preservation during laparoscopic and robotic radical prostatectomy. Journal of Robotic Surgery 7(1):1-8, 2013.
142. Ahrar K, Ahrar JU, Javadi S, Pan L, Milton DR, Wood CG, Matin SF, Stafford RJ. Real-Time Magnetic Resonance Imaging-Guided Cryoablation of Small Renal Tumors at 1.5 T. Invest Radiol. e-Pub 2013. PMID: 23511191.
143. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin SF, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urol 62(6):1013-9, 2012. e-Pub 2012. PMID: 22771265.
144. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, Shariat SF. Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. Ann Surg Oncol 19(13):4337-44, 2012. e-Pub 2012. PMID: 22805867.
145. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Poupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. European Urology 62(1):100-114, 2012.
146. Pisters PW, Pettaway CA, Liu P, Matin SF, Ward JF, Leibovici D. Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective?. J Surg Oncol 106(1):62-5, 2012. e-Pub 2012. PMID: 22259198.
147. Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: Impact of time to surgery. Urol Oncol 30(3):266-272, 2012. e-Pub 2010. PMID: 20869888.
148. Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin SF, Montorsi F, Zerbib M, Shariat SF. Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Eur Urol. e-Pub 2012. PMID: 22579047.
149. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int. e-Pub 2012. PMID: 22503066.
150. Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health 15(2):367-75, 2012. e-Pub 2011. PMID: 22433769.
151. Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, Rosser CJ, Wood CG, Matin SF. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol 187(3):822-6, 2012. e-Pub 2012. PMID: 22245327.
152. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273-9, 2011.
153. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 22(12):2661-6, 2011.
154. Tan W, Hildebrandt MA, Pu X, Huang M, Lin J, Matin SF, Tamboli P, Wood CG, Wu X. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol 186(5):2071-7, 2011.
155. Delacroix SE, Chapin BF, Chen JJ, Nogueras-Gonzalez GM, Tamboli P, Matin SF, Wood CG. Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma?. J Urol 186(4):1236-41, 2011.
156. Davis JW, Achim M, Munsell M, Matin SF. Effectiveness of postgraduate training for learning extraperitoneal access for robot-assisted radical prostatectomy. J Endourol 25(8):1363-9, 2011.
157. Abel EJ, Karam JA, Carrasco A, Matin SF. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol 25(8):1323-7, 2011.
158. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-67, 2011.
159. Kaur H, Matin SF, Javadi S, Johnson VE, Choi H, Sandler C, Ahrar K. Chyluria after radiofrequency ablation of renal tumors. J Vasc Interv Radiol 22(7):924-7, 2011.
160. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22(5):1048-53, 2011.
161. Fernández MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. e-Pub 2011. PMID: 21396845.
162. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2011.
163. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted therapy in patients with metastatic renal cell carcinioma: practical implications for timing of pre-surgical therapy. European Urology 59(1):10-15, 2011.
164. Clark MA, Shikanov S, Raman JD, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang WC, Shalhav AL, Eggener SE. Chronic kidney disease before and after partial nephrectomy. J Urol 185(1):43-8, 2011. e-Pub 2010. PMID: 21074205.
165. Dhillon J, Tannir NM, Matin SF, Tamboli P, Czerniak BA, GUo CC.. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol 42(1):146-50, 2011.
166. Svatek RS, Fisher MB. Matin SF, Kamat AM, Grossman HB, Nogueras-Gonzalez GM, Urbauer DL, Dinney CP.. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology 76(6):1419-24, 2010.
167. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radiofrequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urology 184(5):1882-1887, 2010. e-Pub 2010. PMID: 20846689.
168. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: Comparison with nephrectomy assessment. J Urol 184(5):1877-1881, 2010. e-Pub 2010. PMID: 20850148.
169. Matin SF, Kamat A, Grossman HB. High frequency endoluminal ultrasonography for as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation. J Ultrasound in Medicine 29(9):1277-1284, 2010. PMID: 20733182.
170. Matin SF, Kamat AK, Wood CG, Grossman HB, Brown GA, Dinney CPN, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-3134, 2010.
171. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer 116(14):3378-3388, 2010. PMID: 20564061.
172. Childs MA, Wood CG, Spiess PE, Debiane LG, Hernandez M, Matin SF, Millikan RE, Siefker-Radtkie A, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol 17(3):5184-5189, 2010. PMID: 20566011.
173. Hoang AN, Vaporcyian AA, Matin SF. Laparoscopy-assisted radical nephrectomy with inferior vena caval thrombectomy for level II to III tumor thrombus: a single-institution experience and review of the literature. J Endourol 24(6):1005-12, 2010. PMID: 20491594.
174. Shikanov S, Lifshitz D, Chan AA, Okhunov Z, Ordonez A, Wheat JC, Matin SF, Landman J, Wolf Jr S, Eggener SE,Shalhav AL. Impact of ischemia on renal function after laparoscopic partial nephrectomy: A multicenter study. Journal of Urology 183(5):1714-1718, 2010.
175. Davis JW. Kamat A. Munsell M. Pettaway C. Pisters L. Matin SF. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized?. BJU International 105(8):1148-54, 2010.
176. Chan A, Wood CG, Caicedo J,Munsell MF, Matin SF. Predictors of unilateral renal function after open and laparoscopic partial nephrectomy. Urology 75(2):295-302, 2010. e-Pub 2009. PMID: 19963245.
177. Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site hernias occuring after the use of bladeless radially expanding trocars. Urology 75:574-580, 2010. e-Pub 2009. PMID: 19854489.
178. Matin SF, Sharma P, Gill IS, Tannenbaum C, Hobart MG, Novick AC, Finke JH. Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 183(1):333-338, 2010.
179. Abel EJ, Culp SH, Meissner M, Matin SF, Tamboli P, Wood CG. Identifying the risk for disease progression after surgery for localized renal cell carcinoma. BJU International 106(9):1277-1283, 2010. e-Pub 2010. PMID: 20394619.
180. Svatek RS, Fisher MB, Matin SF, Kamat AM, Grossman HB, Nogueras-Gonzalez GM, Urbauer DL, Kennedy KA, Dinney CP. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol 183(3):929-934, 2010.
181. Raman JD, Raj GV, Lucas SM, Williams SK, Lauer EM, Ahrar K, Matin SF, Leveillee RJ, Cadeddu JA. Renal function outcomes for tumours in a solitary kidney managed by ablative or extirpative techniques. BJU International 105(4):496-500, 2010.
182. Javadi S, Ahrar JU, Ninan E, Gupta NE, Matin SF, Ahrar K. Characterization of contrast enhancement in the ablation zone immediately after radiofrequency ablation of renal tumors. Journal of Vascular & Interventional Radiology 21(5):690-695, 2010.
183. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-4081, 2009. e-Pub 2009.
184. Fisher M, Svatek R, Hegarty PK, McGinnis JE, Hightower C, Grossman HB, Kamat AM, Dinney CPN, Matin SF. Cardiac history and risk of post-cystectomy cardiac complication. Urology, 2009. e-Pub 2009.
185. Clague J, Lin J, Cassidy A, Matin SF, Tannir N, Tamboli P, Wood C, Wu X. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiology, Biomarkers and Prevention 18(3):801-807, 2009. e-Pub 2009.
186. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. A randomized trial of adjuvant thalidomide versus observation in patients with completely resected high risk cell carcinoma. Journal of Urology 73(2):337-341, 2009. e-Pub 2008.
187. Matin SF, Feeley T, Kennamer D, Corriere J, Miles M, Kays C,Green H, Craig C, Dinney C. Office cystoscopy and transrectal ultrasound-guided prostate biopsies pose minimal risk: A prospective evaluation of 921 procedures. Urology 73(6):1175-1178, 2009.
188. Zorn C, Gautam G, Shalhav L, Clayman V, Ahlering E, Albala M, Lee I, Sundaram P, Matin SF, Castle P, Winfield N, Samadi G, Gettman T, Lee R, Thomas R, Patel R, Leveillee J, Wong C, Badlani H, Rha H, Eggener E, Joseph V, Members of the Society of Urologic Robotic Surgeons (SURS) Committee. Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: Recommendations of the Society of Urologic Robotic Surgeons (SURS). J Urol 182:1126-1132, 2009.
189. Shah SK, Matin SF, Singer EA, Eichel L, Kim HL. Outcomes of laparoscopic partial nephrectomy after fellowship training. Journal of the Society of Laparoendoscopc Surgeons 13(2):154-159, 2009.
190. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, Russo P, Uzzo RG. Guideline for management of the clinical T1 renal mass. Journal of Urology 182(4):1271-1279, 2009.
191. Davis JW, Kamat AM, Munsell MF, Pettaway CA, Pisters LL, Matin SF. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: Can training be evaluated and standardized?. BJU Int 105(8):1148-1154, 2009.
192. Lin J, Pu X, Wang W, Matin SF, Tannir NM, Wood CG, Wu X. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma carcinogenesis 29(11):2112-2119, 2008. e-Pub 2008.
193. Rich TA, Jonasch E, Matin SF, Waguespack SG, Gombos DS, Santarpia L, Stolle C, Jimenez C. A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. Cancer Investigation 26(6):642-646, 2008.
194. Matin SF, Tinkey PT, Borne AT, Stephens LC, Sherz A, Swanson DA. A pilot trial of vascular targeted photodynamic therapy for renal tissue. Journal of Urology 180(1):338-342, 2008.
195. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112(7):1480-8, 2008.
196. Ponsky L, Cherullo E, Moinzadeh A, Desai M, Kaouk J, Haber GP, Chen D, Ng C, Fuchs G, Singh D, Finelli A, Matin SF. The Hem-o-lok clip is safe for laparoscopic nephrectomy: a multi-institutional review. Urology 71(4):593-6, 2008. e-Pub 2008.
197. Busby JE, Brown GA, Matin SF. Comparing lymphadenectomy during radical nephroureterectomy: open versus laparoscopic. Urology 71(3):413-6, 2008.
198. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. Journal of Urology 180(1):94-98, 2008.
199. Shao L, Wood CG, Zhang D, Tannir NM, Matin SF, Dinney CP, Wu XF. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178 (4):1492-1496, 2008.
200. Sabichi L, Lerner P, Atkinson E, Grossman H, Caraway P, Dinney P, Penson F, Matin SF, Kamat A, Pisters L, Lin W, Katz L, Brenner E, Hemstreet III P, Wargo M, Bleyer A, Sanders H, Clifford L, Parnes L, Lippman M. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 14:224-229, 2008.
201. Jain M, Matin SF, Kamat A. Inferior vena cava atresia associated with von Hippel-Lindau masquerading as metastatic testicular cancer. Current Urology 2:214-216, 2008.
202. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Location of extrarenal tumor Extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 178(5):1878-1882, 2007.
203. Javadi S, Matin SF, Tamboli P, Ahrar K. Unexpected atypical findings on CT after radiofrequency ablation for small renal-cell carcinoma and the role of percutaneous biopsy. J Vasc Interv Radiol 18(9):1186-1191, 2007.
204. Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70(2):252-256, 2007.
205. Shao L, Wood CG, Zhang D, Tannir NM, Matin SF, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178(4):1186-1191, 2007.
206. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin SF, Swanson DA, Wood CG.. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclea cell histology. J Urol 69(5):819-823, 2007.
207. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG.. Cytoreductive neprectomy in the elderly patient: the M.D. Anderson Cancer Center experience. J Urol 177(3):855-861, 2007.
208. Brown GA and Matin SF. Laparoscopic partial nephrectomy: Experience in 60 cases. J Endourol 21(1):71-74, 2007.
209. Jacobsohn KM, Ahrar K, Wood CG, Matin SF. Is radiofrequency ablation safe for solitary kidneys?. Urology 69(5):819-823, 2007.
210. Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Redefining pPT3 renal cell carcinoma in the modern era: A proposal for a revision of the current TNM primary tumor classification system. Cancer 109(2):2439-2444, 2007.
211. Black PC, Basen-Engquist K, Wang X, Swartz RJ, Eddings T, Matin SF, Swanson D, Wood CG, Pisters LL, Babaian RJ, Troncoso P, Pettaway CA.. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial. BJU Int 100(1):63-9, 2007.
212. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int 98:1176-1180, 2006. PMID: 17125474.
213. Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RA, Uzzo RG, Haaga J, Resnick MI, Kaouk J, Gill IS. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol 176:1973-1977, 2006. PMID: 17070224.
214. Matin SF, Dhanani N, Acosta M, Wood CG. Conventional and hand-assisted laparoscopic radical nephrectomy: Comparative analysis of 271 cases. J Endourol 20:891-894, 2006. PMID: 17144857.
215. Matin SF, Madsen LT, Wood CG. Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center experience. Urology 68:528-532, 2006. PMID: 16979706.
216. Matin SF. Recognition and preservation of accessory pudendal arteries during laparoscopic radical prostatectomy. Urology 67:1012-1015, 2006. PMID: 16635507.
217. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67(3):518-23, 2006. PMID: 16527570.
218. Berglund RK, Matin SF, Desai M, Kaouk J, Gill IS. Laparoscopic radical cystoprostatectomy with bilateral nephroureterectomy: initial report. BJU Int 97:37-41, 2006. PMID: 16336325.
219. Goel MC, Matin SF, Derweesh I, Levin H, Streem S, Novick AC. Partial nephrectomy for renal urothelial tumors: Clinical update. Urology 67:490-495, 2006.
220. Naude AM, Heyns CF, Matin SF. Laparoscopic urology training in South Africa. J Endourol 19:1180-1184, 2005. PMID: 16359210.
221. Ahrar K, Matin SF, Wallace MJ, Gupta S, Hicks ME. Percutaneous transthoracic radiofrequency ablation of renal tumors using an iatrogenic pneumothorax. AJR Am J Roentgenol 185(1):86-88, 2005. PMID: 15972404.
222. Cohen DD, Matin SF, Steinberg JR, Zagone R, Wood CG. Evaluation of the intact specimen after laparoscopic radical nephrectomy for clinically localized renal cell carcinoma identifies a subset of patients at increased risk for recurrence. J Urol 173(5):1487-1491, 2005. PMID: 15821465.
223. Highshaw RA, Vakar-Lopez F, Jonasch E, Yasko AW, Matin SF. Port-site metastasis: the influence of biology. Eur Urol 47:357-360, 2005. PMID: 15716201.
224. Matin SF, Gill IS. Recurrence and survival following laparoscopic radical nephroureterectomy with various forms of bladder cuff control. J Urol 173:395-400, 2005. PMID: 15643179.
225. Stage AC, Pollock RE, Matin SF. Bilateral metastatic renal synovial sarcoma. Urology 65)2):389, 2005. PMID: 15708068.
226. Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney AM, Kaouk JH, Gill IS. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol 173(1):38-41, 2005. PMID: 15592021.
227. Ahrar K, Matin SF, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: Technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-688, 2005.
228. Ahrar K, Matin SF, Wood CG, Gupta S, Wallace MJ, Madoff DC. Utility of contrast-enhanced CT during percutaneous RFA of solid renal tumors. Am J Roentgenol 182(4):13, 2004.
229. Kuang W, Shin PR, Matin SF, Thomas AJ, Jr. Initial evaluation of robotic technology for microsurgical vasovasostomy. J Urol 171(1):300-303, 2004. PMID: 14665899.
230. Matin SF, Abreu S, Ramani A, Steinberg AP, Desai M, Strzempkowski B, Yang Y, Shen Y, Gill IS. Evaluation of age and comorbidity as risk factors after laparoscopic urological surgery. J Urol 170(4):1115-1120, 2003. PMID: 14501704.
231. Matin SF, Yost A, Streem SB. Ureteroscopic laser endopyelotomy: a single-center experience. J Endourol 17(6):401-404, 2003. PMID: 12965067.
232. Matin SF. Prospective randomized trial of skin adhesive versus sutures for closure of 217 laparoscopic port-site incisions. J Am Coll Surg 196(6):845-853, 2003. PMID: 12788419.
233. Matin SF, Gill IS. Modified Pfannenstiel incision for intact specimen extraction after retroperitoneoscopic renal surgery. Urology 61(4):830-832, 2003. PMID: 12670577.
234. Desai MM, Gill IS, Ramani AP, Matin SF, Kaouk JH, Campero JM. Laparoscopic radical nephrectomy for cancer with level I renal vein involvement. J Urol 169(2):487-491, 2003. PMID: 12544294.
235. Bandyopadhyay SK, Rackley RR, Matin SF, Sadhukhan PC. Interferon-alpha response and signal transduction pathway in transitional carcinoma cell lines. Adv Exp Med Biol 539:15-32, 2003. PMID: 15088893.
236. Gill IS, Matin SF, Desai MM, Kaouk JH, Steinberg A, Mascha E, Thornton J, Sherief M, Strzempkowski B, Novick AC. Comparative analysis of laparoscopic and open partial nephrectomy for renal tumors in 200 patients. J Urol 170(1):64-66, 2003.
237. Desai M, Gill IS, Kaouk JH, Matin SF, Novick AC. Laparoscopic partial nephrectomy with suture repair of the pelvicaliceal system. Urology 61(1):99-104, 2003.
238. Desai MM, Gill IS, Kaouk JH, Matin SF, Sung GT, Bravo EL. Robotic-assisted laparoscopic adrenalectomy. Urology 60(6):1104-1107, 2002. PMID: 12475680.
239. Kaouk JH, Matin SF, Bravo EL, Gill IS. Laparoscopic bilateral partial adrenalectomy for pheochromocytoma. Urology 60:1100-1103, 2002. PMID: 12475679.
240. Matin SF, Hsu TH, Klein EA, Streem SB. Acute renal failure due to subcapsular renal hematoma in a solitary kidney: improvement after decompression. J Urol 168(6):2526-2527, 2002. PMID: 12441956.
241. Kuang W, Ng CS, Matin SF, Kaouk JH, El-Jack M, Gill IS. Rhabdomyolysis after laparoscopic donor nephrectomy. Urology 60(5):911-912, 2002. PMID: 12429334.
242. Matin SF, Gill IS, Worley S, Novick AC. Outcome of laparoscopic radical and open partial nephrectomy for the sporadic 4 cm. or less renal tumor with a normal contralateral kidney. J Urol 168(4):1356-1359, 2002. PMID: 12352392.
243. Goldfarb DA, Matin SF, Braun WE, Schreiber MJ, Mastroianni B, Papajcik D, Rolin HA, Flechner S, Goormastic M, Novick AC. Renal outcome 25 years after donor nephrectomy. J Urol 166(6):2043-2047, 2001. PMID: 11696703.
244. Matin SF, Yost A, Streem SB. Extracorporeal shock-wave lithotripsy: a comparative study of electrohydraulic and electromagnetic units. J Urol 166(6):2053-2056, 2001. PMID: 11696705.
245. Hsu TH, Matin SF. Benign prostatic hyperplasia mimicking bladder tumor. Urology 57(6):1166, 2001. PMID: 11377336.
246. Matin SF, Novick AC. Renal dysfunction associated with staged bilateral partial nephrectomy: the importance of operative positioning. J Urol 165(3):880-881, 2001. PMID: 11176491.
247. Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res 61(5):2261-2266, 2001. PMID: 11280796.
248. Matin SF, Streem SB. Metabolic risk factors in patients with ureteropelvic junction obstruction and renal calculi. J Urol 163(6):1676-1678, 2000. PMID: 10799158.
249. Matin SF, Gill IS. Laparoscopic marsupialization of the difficult lymphocele using internalized peritoneal dialysis catheter. J Urol 163(6):1498-1500, 2000. PMID: 10751865.
250. Rackley RR, Bandyopadhyay SK, Matin SF, Shin MS, Appell R. Immunoregulatory potential of urothelium: characterization of NF-kappaB signal transduction. J Urol 162(5):1812-1816, 1999. PMID: 10524940.
251. Matin SF, Gill IS, Hsu TH, Sung GT, Novick AC,. Laparoscopic renal and adrenal surgery in obese patients: comparison to open surgery. J Urol 162:665-669, 1999. PMID: 10458337.
252. Hsu TH, Gill IS, Matin SF, Soble JJ, Sung GT, Schweizer D, Novick AC. Radical nephrectomy and nephroureterectomy in the octogenarian and nonagenarian: comparison of laparoscopic and open approaches. Urology 53(6):1121-1125, 1999. PMID: 10367839.
253. Matin SF, Novick AC. Nephron-sparing surgery for renal angiomyolipoma. Urology 52(4):577-583, 1998. PMID: 9763074.
254. Matin SF, Montague DK, Angermeier KW, Lakin MM. Penile fracture after intracavernous injection therapy. J Urol 159(6):2094, 1998. PMID: 9598535.
255. Matin SF, Streem SB. Nephron sparing management of Fraley's syndrome with a pyelopyelostomy. J Urol 159(2):487-489, 1998. PMID: 9649268.
256. Matin SF, Goldfarb DA, Novick AC. Upper tract surgery in pregnancy. Urology 52(3):510-511, 1998.
257. Matin SF, Rackely R, Bandyopadhyay S. Defective interferon-alpha signaling in transitional cell carcinoma. Eur Cytokine Netw 9:506-507, 1998.
258. Matin SF, Levin HS, Streem SB. Ureteroscopic diagnosis of intraluminal metastatic rectal carcinoma. Urology 49(6):955-956, 1997.

Invited Articles

1. Kokorovic A, Matin SF. UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma. Ther Adv Med Oncol 12:1758835920937950, 2020. e-Pub 2020. PMID: 32670424.
2. Lim A, Rao P, Matin SF. Lynch syndrome and urologic malignancies: a contemporary review. Curr Opin Urol. e-Pub 2019. PMID: 31045926.
3. Matin SF. The Role of Lymph Node Dissection for Upper Tract Tumors. AUA News 24(2):3-4, 2019.
4. Huang D, Matin SF, Lawrentschuk N, Roupret M. Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome. Bladder Cancer 4(3):261-268, 2018. e-Pub 2018. PMID: 30112437.
5. Petros FG, Li R, Matin SF. Endoscopic Approaches to Upper Tract Urothelial Carcinoma. Urol Clin North Am 45(2):267-286, 2018. e-Pub 2018. PMID: 29650142.
6. Petros FG, Matin SF. Re: Association Between Lymph Node Yield and Survival Among Patients Undergoing Radical Nephroureterectomy for Urothelial Carcinoma of the Upper Tract. Eur Urol 123:1741-50. e-Pub 2017. PMID: 29249290.
7. Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol 35(7):492-498, 2017. e-Pub 2017. PMID: 28579283.
8. Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol 35(3):327-335, 2017. e-Pub 2016. PMID: 27043218.
9. Mandalapu RS, Remzi M, de Reijke TM, Margulis V, Palou J, Kapoor A, Yossepowitch O, Coleman J, Traxer O, Anderson JK, Catto J, de la Rosette J, O'Brien T, Zlotta A, Matin SF. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol 35(3):355-365, 2017. e-Pub 2016. PMID: 27233780.
10. Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF. Upper Urinary Tract Carcinoma in Situ: Current Knowledge, Future Direction. J Urol 197(2):287-295, 2017. e-Pub 2016. PMID: 27664578.
11. Matin SF. Tribute to Dr. David Swanson. Urology 95:1, 2016.
12. Mandalapu RS, Matin SF. Contemporary Evaluation and Management of Upper Tract Urothelial Cancer. Urology 94:17-23, 2016. e-Pub 2016. PMID: 26850816.
13. Matin SF. Quality-of-life Outcomes in Patients with Small Renal Masses. Nature Reviews 13(8):443, 2016.
14. Matin SF, Melquist J, Karam JA. Author reply. Urology 87:222-3, 2016. PMID: 27243090.
15. Matin SF, McConkey DJ. Bridging the Gap in Upper Tract Urothelial Carcinoma. Eur Urol 68(6):978-9, 2015. e-Pub 2015. PMID: 26298210.
16. Satcher RL, Bogler O, Hyle L, Lee A, Simmon A, Williams R, Hawk E, Matin SF, Brewster AM. Telemedicine and telesurgery in cancer care: Inaugural conference at MD Anderson Cancer Center. J Surg Oncol. e-Pub 2014. PMID: 24889208.
17. Matin SF. A New Era in the Treatment of Genetic Renal Tumor Syndromes Re: Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Re:Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2. Eur Urol 63(4), 2013.
18. Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: Report from a consensus panel. BJU Int 110(7):942-8, 2012. e-Pub 2012. PMID: 22462566.
19. Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol 9(5):266-273, 2012. e-Pub 2012. PMID: 22487872.
20. Chan AA, Ahrar K, Matin SF. Ablative therapies in renal cell carcinoma. Minerva Urol Nefrol 63(3):237-50, 2011.
21. Karam JA, Ahrar K, Matin SF. Ablation of kidney tumors. Surg Oncol Clin N Am 20(2):341-53, viii, 2011.
22. Vikram R, Na CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood C, Sandler CM. Papillary Renal Cell Carcinoma: Radiologic - Pathologic Correlation and Spectrum of Disease. RadioGraphics 29(3):741-757, 2009.
23. Chung BI, Ost MC, Matin SF, Winfield HN. Fellowship in Endourology, the Job Search, and Setting up a Successful Practice: An Insider's View. J. Endourology 22(3):551-558, 2008.
24. Matin SF, Ahrar K. Nephron-sparing probe ablative therapy: long- term outcomes. Current Opinion in Urology 18(2):150-156, 2008.
25. Margulis V, Matin SF, Wood CG. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Cur Opin Urol 18(5):474-480, 2008.
26. Kundra V, Silverman P, Matin SF, Choi H. Imaging in Oncology from the University of Texas M. D. Anderson Cancer Center: Imaging in the Diagnosis, Staging and Surveillance of Prostate Cancer. AJR Am J Roentgenol 189(4):830-844, 2007.
27. Busby JE, Matin SF. Laparoscopic radical nephroureterectomy for transitional cell carcinoma: Where are we in 2007?. Cur Opin Urol 17(2):83-87, 2007.
28. Matin SF. Renal tumors: Newer treatments are here, but new measures for patient quality of life are needed. Urology Health Extra Spring Issue 1:5, 2006.
29. Ahrar K, Wallace MJ, Matin SF. Percutaneous Radiofrequency Ablation: Minimally Invasive Therapy for Renal Tumors. Expert Rev Anticancer Ther 6(12):1735-1744, 2006.
30. Canfield S, Matin SF. Laparoscopic urologic oncology. Contemporary Urology:38-54, 2005.
31. Matin SF. Radical laparoscopic radical nephroureterectomy: current status. BJU International 95(2):68-74, 2005.
32. Matin SF. Laparoscopic approaches to urologic malignancies. Curr Treat Options Oncol 4(5):373-383, 2004.
33. Matin SF. Laparoscopic approaches to urologic malignancies. The American Journal of Urology Review 2(4):166-173, 2004.
34. Steinberg JR, Matin SF. Laparoscopic radical nephroureterectomy: dilemma of the distal ureter. Curr Opinion Urology 14(2):61-65, 2004.
35. Bandyopadhyay Sk, Rackley RR, Matin SF, Sadhukhan PC,. Interferon-alpha response and signal trasduction pathway in transitional carcinoma cell lines. Advances in Eperimental Medicine & Biology:539 (PtA):15-32, 2003.
36. Matin SF, Gill IS. Laparoscopic radical cystectomy with urinary diversion: completely intracorporeal technique. J. Endourology 16(6):335-341, 2002.
37. Matin SF, Gill IS. Laparoscopic radical nephrectomy: retroperitoneal versus transperitoneal approach. Curr Urol Rep 3(2):164-171, 2002.
38. Matin SF, Gill IS. Laparoscopic ultrasonography. J. Endourology 15(1):87-92, 2001.

Manuals, Teaching Aids, Other Teaching Publications

1. Margulis V, Matin SF. Upper Tract Urothelial Carcinoma Urology Core Curriculum. American Urological Association, 2015.
2. Lotan Y, Matin SF, Margulis V. Upper Tract Neoplasms. American Urological Association University, 2014.
3. Matin SF. Prostate Health Conference: Laparoscopic Prostatectomy, 2011.
4. Matin SF. RFA Shows Promise as Treatment Alternative in Selected Renal Cancer Patients. The ASCO Post, 2010.
5. Matin SF. A Leap of Technology; The future of surgery. MD Anderson Newsletter Messenger, 2010.
6. Matin SF. A Brief History of Prostate Cancer, New Findings and treatments. Network, A Publication of the Anderson Network: Houston, 2006.
7. Matin SF. A State-Of-The-Arm System. Messenger, A Publication of M. D. Anderson Cancer Center: Houston, 2006.
8. Matin SF. Laparoscopic radical prostatectomy. National Cancer Newswire Television News Segment (via M. D. Anderson Communications Department) for various regional and national television stations: Houston, 2005.
9. Matin SF. Better RCC Therapy Options. Renal and Urology News by John Schiezer, 2005.
10. Matin SF. Laparoscopy Shows a Benefit in a Growing Number of Oncologic Procedures. M. D. Anderson Cancer Center OncoLog: Houston, 2003.
11. Fischman J, Matin SF. The Advantages of Prostate Surgery. U. S. News, Commentary by Josh Fischman, 2002.
12. Matin SF. A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer. KTRK, Channel 13 Commentary Interview regarding New England Journal of Medicine Article with Christie Meyers, ABC local affiliate, 2002.

Other Articles

1. Hensley PJ, Labbate CV, Matin SF Beyond the Abstract: Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Uro Onc Seminars 40(10):454, 2022.
2. Additional Contributor Implications for Telehealth in a Postpandemic Future Regulatory and Privacy Issues. JAMA Network, 2020.

Editorials

1. Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ. Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.03.003. Eur Urol Oncol 6(6):638-639, 2023. PMID: 37268448.
2. Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6. Eur Urol 84(2):e55-e56, 2023. PMID: 37149462.
3. Labbate CV, Adibi M, Matin SF. Editorial Comment. J Urol. PMID: 35236102.
4. Westerman ME, Matin SF. EDITORIAL COMMENT. Urology 156:160-161, 2021. PMID: 34758553.
5. Miest TS, Matin SF. Editorial Comment: Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). J Urol:101097JU000000000000178602. PMID: 34105990.
6. Sharma V, Miest TS, Juvet TS, Toussi A, Packiam V, Chamie K, Matin SF, Boorjian SA, Thompson RH, Frank I, Tollefson MK, Potretzke AM. Reply by Authors. J Urol:101097JU000000000000183402. PMID: 34121427.
7. Adibi M, Matin SF. Editorial Comment: Endoscopic Treatment for Large Multifocal Upper Tract Urothelial Carcinoma. J Urol:101097JU000000000000150501. PMID: 33476195.
8. Geynisman DM, Kadow BT, Shuch BM, Boorjian SA,Matin SF, Rampersaud E, Milestone BN, Plimack ER, Zibelman MR, Kutikov A, Smaldone MC, Chen DY, Viterbo R, Joshi S, Greenberg RE, Malizzia L, McGowan T, Ross EA, Uzzo RG. Reply by Authors. J Urol 204(3):536-537, 2020. PMID: 32574522.
9. Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J, Collaborators. Reply by Authors. J Urol 203(4):101097JU000000000000064402, 2020. PMID: 31967495.
10. Stamatakis L, Matin SF. EDITORIAL COMMENT: Upper Tract Urothelial CarcinomaGrade Prediction Based on theUreteroscopic Appearance: CautionShould be Taken. Urology 132:74, 2019. PMID: 31582000.
11. Jonasch E, Matin SF. The first prospective trial for von Hippel-Lindau disease:. Lancet Oncology, 2018.
12. Matin SF. Editorial Comment. J Urol 199(4):933-939, 2018. PMID: 29037861.
13. Commentary: Meissner MA, McCormick BZ, Matin SF, Wood CG, Karam JA. Radical Nephrectomy is the Treatment of Choice for Complex, Localized Renal Tumors. Kidney Cancer 2(2018):5-9, 2018.
14. Matin SF. Commentary: Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. The Journal of Urology 185(6):2428-2430, 2017.
15. Matin SF. Editorial Comment. J Urol. PMID: 28551454.
16. Ferguson JE, Matin SF. Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. Eur Urol. PMID: 28237787.
17. Petros FG, Matin SF. Cryoablation for cT1b Renal Tumors? Yet to Be Determined. Eur Urol 71(1):118-119, 2017. PMID: 27616722.
18. Metcalfe MJ, Matin SF. Editorial Comment. Urology. PMID: 27993389.
19. Matin SF. Kidney cancer: Quality-of-life outcomes in patients with small renal masses. Nat Rev Urol 13(8):443-4, 2016. PMID: 27400666.
20. Sabir S, Ahrar K, Matin SF. Predicting and Determining the Success of Percutaneous Ablation. J Urol 196(1):7-8, 2016. PMID: 27086180.
21. Karam JA, Matin SF. Positive Margins after Radical Nephrectomy with Venous Thrombectomy: Controversies and Treatment Options. J Urol 195(2):241-2, 2016. PMID: 26585683.
22. Navai N, Matin SF. Re: A Randomized Trial of Robot-assisted Laparoscopic Radical Cystectomy. Eur Urol 67(1):173-4, 2015. PMID: 25528394.
23. Matin SF. 'Discontent is the first necessity of progress', Thomas A. Edison. BJU Int 114(5):635, 2014. PMID: 25339071.
24. Matin SF. Editorial comment: Parenchymal Volume Preservation and Ischemia During Partial Nephrectomy: Functional and Volumetric Analysis. Urology 82(2):268-9; discussion 269, 2013. PMID: 23791216.
25. Matin SF. Accepting the positive results of unconventional methods. BJU International 112(1):5-6, 2013. PMID: 23759004.
26. Hurel S, Rouprêt M, Ouzzane A, Rozet F, Xylinas E, Zerbib M, Berod AA, Ruffion A, Adam E, Cussenot O, Houlgatte A, Phé V, Nouhaud FX, Bensadoun H, Delage F, Guillotreau J, Guy L, Karsenty G, De La Taille A, Colin P, French Collaborative National Database on UTUC. Impact of Lymphovascular Invasion on Oncologic Outcomes in Patients with Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. BJU Int 111(8):1199-207, 2013. PMID: 23650914.
27. Matin SF. Editorial Comment: Robot-Assisted Radical Prostatectomy Outcomes: 5-Year Oncological and Biochemical Outcomes. J Urol 188(6):2211, 2012. PMID: 23083659.
28. Matin SF. Commentary: Okhunov Z, Roy O, Duty B, Waingankar N, Herati A, Morgenstern N, Sheikh-Fayyaz S, Kavoussi LR. Clinical evaluation of a novel bipolar radiofrequency ablation system for renal masses. Journal of Endourology 26(11):1392-1408, 2012.
29. Matin SF. Commentary: Pietryga JA, Beland MD, Dupuy DE, Mayo-Smith WW. Placement of marker coils at biopsy: usefulness in the localization of poorly visualized renal neoplasms for subsequent CT-guided radiofrequency ablation. Journal of Endourology 26(11):1392-1408, 2012.
30. Matin SF. RE: Functional recovery after partial nephrectomy: effects of volume loss and ischemic injury: M. N. Simmons, S. P. Hillyer, B. H. Lee, A. F. Fergany, J. Kaouk and S. C. Campbell. J Urol 2012; 187: 1667-1673. J Urol 188(3):1048-9, 2012. PMID: 22819102.
31. Navai N, Matin SF. Commentary: Bartoletti R, et al.. In vivo microwave-induced porcine kidney thermoablation: results and perspectives from a pilot study of a new probe. Journal of Endourology 25(6):908-9, 2011.
32. Navai N, Matin SF. Commentary: Glazer ES, et al.. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Journal of Endourology 25(6):909-10, 2011.
33. Matin SF. Commentary: Benhammpi JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. J Urol 184(5):1855-9, 2010. PMID: 20846682.
34. Matin SF. Commentary: Matin SF.. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Appeared in www.urotoday.com "Beyond the Abstract" section, 2010.
35. Matin SF. Commentary: Littrup PJ, et al.; Matin SF, et al.. Survey of Endourology: Thermal/Ablative Technology. Journal of Endourology 24(6):885-898, 2010.
36. Matin SF. Commentary: Matin SF.. Determining failure after renal ablative therapy for renal cell carcinoma: false negative and false positive imaging findings. Urology 75(6):1254-1257, 2010.
37. Matin SF. Emergence of robot-assisted partial nephrectomy. Nature Reviews Urology 6(11):579-580, 2009.
38. Matin SF. Commentary: Kunkle DA, et al.; Hinshaw JL, et al.. Survey of Endourology. J Endourol 23(6):879-890, 2009.
39. Matin SF. Commentary: Medioni J, et al.. Response of Renal Cell Carcinoma Pancreatic Metastasis to Sunitinib Treatment: Retrospective Analysis. Journal of Urology 181(6):2470-2475, 2009.
40. Matin SF. Commentary: Raman JD, et al.; Nguyen CT, et al.; Johnson A, et al.. Survey of Endourology. J Endourol 22(11):2413-2414, 2008.
41. Matin SF. Commentary: Gallucci M, et al. Superselective embolization as first step of laparoscopic partial nephrectomy. Urology 69(4):645-646, 2007.
42. Matin SF. Commentary: Breda A, et al. Positive margins in laparoscopic partial nephrectomy in 855 cases: A multi-institutional survey from the United States and Europe. The Journal of Urology 178(1):50, 2007.
43. Matin SF. Commentary: Snyder ME, et al.. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: Influence of sex. The Journal of Urology 176(6):2395-2396, 2006.
44. Matin SF, Jonasch EE. Targeting von Hippel-Lindau syndrome: the future is now. Future Oncol 2(3):321-324, 2006.

Abstracts

1. Das A, Shapiro D, Karam J, Master V, Spiess P, Raman J, Esdaille A, Zemp L, Sharma P, Sexton W, Patil D, Allen G, Matin S, Abel EJ. MP28-01: Cytoreductive Nephrectomy Perioperative Outcomes Have Significantly Improved in Recent Years. The Journal of Urology 209(4S):e369, 2023.
2. Shapiro D, Karam J, Master V, Spiess P, Raman J, Sexton W, Zemp L, Patil D, Lauer K, Allen G, Matin S, Abel EJ. PD24-01: The Selection for CytoREductivE Nephrectomy (SCREEN) Score: Surgical Risk Stratification Integrating Radiographic Features. The Journal of Urology 209(4S):e721, 2023.
3. Caceres JH, Egner T, Labbate C, Matin S, Nagpal S, Huang W, Persily J, Wettstein M, Choe J, Linehan J, Tachibana IT, Kaimakliotis H, Perecman A, Canes D, Raman J. MP58-20: Overall Survival after Endoscopic Treatment of UTUC. The Journal of Urology 209(4S):e804, 2023.
4. Hensley P, Labbate C, Xiao L, Zganjar A, Durdin T, Huelster H, Pham J, Howard J, Pallauf M, Lombardo K, Potretzke A, Spiess P, Raman J, Margulis V, Singla N, Coleman J, Matin S. MP69-11: Predictive Nomogram for Post-Nephroureterectomy GFR Estimation. The Journal of Urology 209(4S):e968, 2023.
5. Hara K, Corredor-Alonso GE, Serrano AG, Hernandez SD, Lu W, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir NM, Msaouel P, Sircar K, Solis LM, Tang C. Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial. Journal of Clinical Oncology 41(6):701, 2023.
6. Abdelsalam M, Awad A, Baiomy A, Karam J, Matin S, Ahrar K. 1- Long-term survival outcome radiofrequency ablation of biopsy proven T1a renal cell carcinoma (RCC). CIRSE 2022, 2022.
7. Abdelsalam M, Mecci N, Awad A, Lu T, Matin S, Karam J, Ahrar K. 2- The survival outcome of MRI guided cryoablation for biopsy proven T1a renal cell carcinoma (RCC). CIRSE 2022, 2022.
8. Hensley PJ, Miest T, Adibi M, Campbell M, Shah A, Cherry L, Papadopoulos J, Siefker-Radtke A, Gao J, Guo C, Czerniak B, Navai N, Kamat A, Dinney C., Matin SF. GFR fluctuation induced by neoadjuvant chemotherapy correlates with pathologic stage of upper tract urothelial carcinoma. Eur Uro 79(S1):S1090-S1091. e-Pub 2021.
9. Abdelsalam M, Mecci N, Matin S, Wood C, Karam J, Ahrar K. Magnetic resonance imaging–guided cryoablation of de novo solitary pathologically proven T1a renal tumors. Journal of Vascular and Interventional Radiology 32(5):S165. e-Pub 2021.
10. Altok M, Achim M, Matin SF, Pettaway C, Davis J. A Decade of Robot-Assisted Radical Prostatectomy Training: Time-Based Metrics from Fellows and Residents. J Urol 197(4):Supplement, e694-e695, 2017.
11. Achim M, Matin SF, Chapin B, Troncoso P, Tapia ELN, Guerrero M, Prokhorova I, Olson A, Haddad Z, Margrave J, Chelliserry J, Lam L, Yousefi K, Buerki C, Davicioni E, Davis J. Assessing Decipher for predicting lymph node positive disease among men diagnosed with intermediate risk disease treated with prostatectomy and ePLND. J Urol 197(4):Supplement, e848-e849, 2017.
12. Geiger S, Kocher N, Ilinsky D, Xylinas E, Chang P, Dewey L, Wagner AW, Petros F, Matin SF, nrad Tobert C, Tracy C, Pierre-Marie P, Roumiguie M, Monteiro LL, Kassouf W, Raman JD. The Comprehensive Complication Index (CCI) is superior to the Clavien-Dindo grading system in predicting length of stay and hospital readmission following radical nephroureterectomy. J Urol 197(4):Supplement, e878, 2017.
13. Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Petros FG, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM , Wood CG, Dinney CP, Matin SF. Results of Second Line Topical Therapy for Upper Tract Urothelial Carcinoma (UTUC). J Urol 197(4):Supplement, e1030–e1031, 2017.
14. Kocher N, Raman JD, Xylinas E, Chang P, Dewey L, Wagner A, Petros F, Matin SF, Tobert C, Tracy C, Pierre-Marie P, Roumiguie M, Monteiro LL, Kassouf W, Shariat F, Klatte T. External validation of a preoperative nomogram to predict likelihood of all complications following radical nephroureterectomy. J Urol 197(4):Supplement, e1034, 2017.
15. Kocher N, Raman J, Canes D, Bensalah K, Roupret M, Lallas C, Margulis V, Shariat S, Colin P, Matin SF, Tracy C, Xylinas E, Wagner A, Roumiguie M, Kassouf W, Klatte T. Impaired Baseline Performance Status and Chronic Kidney Disease are Significantly Associated with Major Complications Following Radical Nephroureterectomy. J Urol 197(4):Supplement, e1036, 2017.
16. Damodaran S, Spiess PE, Karam JA, Margulis V, Master VA, Raman JD, Sexton WJ, Patil D, Borregales LD, Robyak H, Matin SF, Wood CG, Abel EJ. Survival following neoadjuvant targeted therapy and cytoreductive nephrectomy in mRCC patients with tumor thrombus; a contemporary multi-institutional series. J Urol 197(4):Supplement, e63, 2017.
17. Keskin S, Petros F, Yu K, Aboshady Y, Borregales L, Kenney P, Matin SF, Karam JA, Wood CG. Should Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma Undergo Cytoreductive Nephrectomy?. J Urol 197(4):Supplement, e65–e66, 2017.
18. Yu K, Keskin SK, Petros FG, Wang X, Borregales LD, Aboshady Y, Gu C, Matin SF, Wood CG, Karam JA. Patients With RCC And Pathologic Nodal Disease Should Be Reclassified As Stage IV. J Urol 197(4):Supplement, e989–e990, 2017.
19. Metcalfe M, Petros F, Rao P, Mork M, Lianchun X, Broaddus R, Matin SF. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol 197(4):Supplement, e1122, 2017.
20. Abdelsalam ME, Sabir SH, Kusin SB, Matin SF, Wood CG, Karam J, Ahrar K. Image Guided Thermal Ablation of pathologically proven T1a Renal cell carcinoma in the setting of other non-renal primary cancer: A Tertiary Cancer Center Experience. 2017 SIR Annual Scientific Meeting, 2017.
21. Campbell MT, Matin SF, Slack R, Sun JJ, Tang DN, Chen H, Blando JM, Zhang L, Rao P, Sharma P. Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma. J Clin Oncol 35:Suppl 6S; abstract 505, 2017.
22. Petros FG, Keskin SK, Yu K, Fellman BM, Metcalfe MJ, Matin SF, Karam JA, Wood CG. Intraoperative conversion from partial to radical nephrectomy: Predictive factors and outcomes. J Clin Oncol 35:Suppl 6S; abstract 483, 2017.
23. Metcalfe MF, Rao P, Mork ME, Petros FG, Xiao L, Broaddus R, Matin SF. Lynch syndrome-associated upper tract urothelial cancer: Assessment of clinical screening criteria and tissue-based point of care testing. J Clin Oncol 35:Suppl 6S; abstract 371, 2017.
24. Keskin SK, Msaouel P, Hess KR, Matin SF, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of patients (pts) with renal cell carcinoma and sarcomatoid dedifferentiation (sRCC) treated with nephrectomy (Nx) and systemic therapies (T) over three decades: The MD Anderson Cancer Center (MDACC) experience. J Clin Oncol 35:SUppl 6S; abstract 534, 2017.
25. Moss TJ, Qi Y, Xi L, Peng B, Mosqueda ME, Guo C, Ittman M, Wheeler DA, Lerner SP, Matin SF. Comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC). J Clin Oncol 35:Suppl 6S; abstract 375, 2017.
26. Abdelsalam ME, Sabir SH, Fellman B, Kusin SB, Wood CG, Matin SF, Karam JA, Ahrar K. Overall Survival After Image Guided Thermal Ablation of Pathologically Proven T1a RCC in Cancer Survivors. 2016 ASCO Annual Meeting, 2016.
27. Chery L, Adibi M, Borregales L, Brandt J, Gu D, Kumar A, Matin SF, Karam J, Wood C. MP75-17 The Risk of Chronic Kidney Disease in the Elderly after Radical or Partial Nephrectomy for Masses Larger than Pt1a. J Urol 195(4S):e985, 2016.
28. Abel EJ, Zargar K, Margulis V, Mann MA, Spiess PE, Ashouri K, Borregales L, Haddad A, Rew C, Chen G, Shi F, Matin SF, Wood C, Karam J. PD04-10 Identifying MRCC Patients with Venous Thrombus Who Are Likely to Benefit from Cytoreductive Surgery. J Urol 195(4S):e123-e124, 2016.
29. Sundi D, Tosoian J, Achim M, Davis J, Pettaway C, Ward J, Matin SF, Pisters L, Schaeffer E, Ross A, Chapin B. MP 9-12 Freedom from Biochemical Recurrence and Metastasis in men with Very High Risk Prostate Cancer Treated at a Tertiary Center: Validation of a New Risk Stratum. J Urol 195(4S):e98, 2016.
30. Altok M, Achim M, Matin SF, Davis J. MP79-14 Extended Template Pelvic Lymph Node Dissection for Intermediate-high Risk Prostate Cancer: A Therapeutic Uncertainty. J Urol 195(4S):e1040, 2016.
31. Jayaratna I, Matin SF, Pettaway C. V1-04: Robotic Assisted Inguinal Lymphadenectomy for Penile Cancer: The MD Anderson Cancer Center Technique. J Urol 195(4s):e62, 2016.
32. Borregales L, Chery L, Adibi M, Thomas A, Wang X, Reis RD, Kumar A, Brandt J, Gu D, Wiemers M, Matin SF, Karam J, Wood C. Long Term Renal Function After Partial Nephrectomy Vs Radical Nephrectomy in Patients with Preexisting Chronic Kidney Disease: A Propensity Score-Matched Analysis. J Urol 195(4S):e706, 2016.
33. Thomas A, Adibi M, Slack R, Borregales L, Merrill M, Tamboli P, Sircar K, Jonasch E, Matin SF, Wood C, Karam J. The role of metastasectomy in patients with renal cell carcinoma with sarcomatoid dedifferentiation: A matched controlled analysis. J Urol 195(4S):e1177, 2016.
34. Bednarski B, Katz M, Papadopoulos J, You N, Rodriguez-Bigas M, Skibber J, Matin SF, Chang G. Telemedicine to Assess Ileostomy Output: A Feasibility Trial, 2016.
35. Matin SF, Espiritu P, Coleman JA, Sfakianos JP, Spiess PE. Patterns of lymphatic metastases in upper tract urothelial carcinoma: Experience from three comprehensive cancer centers. J Clin Oncol 33(Suppl 7), 2015.
36. Williams SB, Davis JW, Achim MF, Zurita AJ, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Effect of neoadjuvant systemic therapy prior to radical prostatectomy in high-risk prostate cancer on surgical morbidity: Contemporary results utilizing the Clavien System. J Clin Oncol 33(Suppl 7), 2015.
37. Thomas AZ, Adibi M, Borregales L, Hoang LN, Tamboli P, Matin SF, Karam JA, Wood CG. Surgical management for local retroperitoneal recurrence after radical nephrectomy in the targeted therapy era. J Clin Oncol 33(Suppl 7), 2015.
38. Adibi M, Thomas AZ, Borregales L, Merrill MM, Sircar K, Tamboli P, Slack R, Chen H, Tannir NM, Jonasch E, Matin SF, Wood CG, Karam JA. Percentage of sarcomatoid component as a prognostic indicator for survival in sarcomatoid renal cell carcinoma. J Clin Oncol 33(Suppl 7), 2015.
39. Siefker-Radtke AO, Choi W, Porten SP, Shen Y, Kamat AM, Matin SF, Dinney CPN, Czerniak B, McConkey DJ. The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC plus bevacizumab. J Clin Oncol 33(Suppl 7), 2015.
40. Borregales L, Kim DY, Qiao W, Tamboli P, Jonasch E, Tannir NM, Matin SF, Wood CG, Karam JA. Outcomes and prognosticators in patients with pathologic T4 renal cell carcinoma. J Clin Oncol 33(Suppl 7), 2015.
41. Liu X, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam JA, Wood CG, Matin SF, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. J Clin Oncol 33(Suppl 7), 2015.
42. Shah AY, Campbell MT, Nautiyal KD, Hashemi N, Matin SF, Vaporciyan AA, Rhines LD, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CG, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(Suppl 7), 2015.
43. Shah AY, Karam JA, Rao P, Jonasch E, Rathmell K, Matin SF, Vaishampayan UN, Heng D, Plimack ER, Guancial EA, Fung C, Lowas SR, Lim ZD, Wood CG, Tannir NM. Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients. J Clin Oncol 33(Suppl 7), 2015.
44. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do K, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. Journal of Clinical Oncology 31(6_suppl), 2013.
45. Porten SP, Gopalakrishnan V, Nogueras-Gonzalez GM, Kamat AM, Siefker-Radtke AO, Dinney CP, Matin SF. Survival of upper tract urothelial carcinoma: A population-based analysis. Journal of Clinical Oncology 31(6_suppl), 2013.
46. Merrill MM, Wood CG, Tannir NM, Slack R, Babaian K, Jonasch E, Pagliaro LC, Compton Z, Tamboli Z, Sircar K, Pisters LL, Matin SF, Karam JA. Characteristics and clinical outcomes of patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). Journal of Clinical Oncology 31(6_suppl), 2013.
47. Conter HJ, Wood CG, Matin SF, Tamboli P, Millikan RE, Jonasch E, Tannir NM. Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. Journal of Clinical Oncology 31(6_suppl), 2013.
48. Porten SP, Siefker-Radtke AO, Kamat AM, Dinney CP, Matin SF. Survival outcomes in patients undergoing neoadjuvant chemotherapy for upper tract urothelial cell carcinoma. Journal of Clinical Oncology 31(6_suppl), 2013.
49. Babaian K, Matin SF, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. Journal of Clinical Oncology 31(6_suppl), 2013.
50. Stafford RJ, Javadi S, Ninan EP, Teniente Y, Pan L, Matin SF, Ahrar K.. MRI- Guided cryoablation of small renal tumors. International Society for Magnetic Resonance in Medicine(6275), 2012.
51. Sietker-Radtke A, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CP. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol:261A, 2012.
52. Zurita AJ, Khajavi M, Wang X, Wood CG, Matin SF, Fiorentino S, Mckee KS, Tran HT, Heymach J, Jonasch E,. Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC). J Clin Oncol:383A, 2012.
53. Abel, JE, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Early primary tumor response is an independent predictor of overall survival in patients with metastatic RCC undergoing treatment with sunitinib. J Urol 185(4):e799-e800, 2011.
54. Raman J, Donnally C, Shingleton WB, Kaplon D, Nakada S, Werle D, Pettus J, Zagoria R, Ordonez A, Landman J, Herati A, Lee B, Ahrar K, Matin SF, Moore C, Leveillee R, Louie M, Clayman R, Cadeddu J. Management of recurrences following cryoablation or radiofrequency ablation (RFA) of renal cortical tumors. J Urol 185(4):e611, 2011.
55. Rajput M, Kamat A, Clavell-Hernandez J, Siefker-Radtke A, Grossman HB, Dinney C, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urninary tract urothelial carcinoma after neoadjuvant chemotherapy. J Urol 185(4):e200, 2011.
56. Margulis V, Matin SF, Jonasch E, Tamboli P, Tannir N, Swanson D, Wood C. Impact of delay from diagnosis to cytoreductive nephrectomy on oncologic outcomes of patients with metastatic renal cell carcinoma. J Urol 183(4):Supplement, e640, 2010.
57. Fernandez M, Parikh S, Dinney C, Grossman HB, Katz R, Matin SF, Kamat A. The role of fish in upper urinary tract surveillance after radical cystectomy for bladder cancer. J Urol 183(4):Supplement, e169, 2010.
58. Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site hernias occurring after the use of bladeless radially expanding trocars. J Urol 183(4):Supplement, e349, 2010.
59. Clark M, Matin SF, Huang W, Shalhav A, Eggener SE. Chronic kidney disease prior and following nephron-sparing surgery. J Urol 183(4):Supplement, e320, 2010.
60. Delacroix S, Culp S, Chen JJ, Tamboli P, Matin SF, Wood C. Retroperitoneal lymph node metastasis in M0 renal cell carcinoma. J Urol 183(4):Supplement, e698, 2010.
61. Clark M, Shikanov S, Raman J, Smith B, Kaag M, Russo P, Wheat JC, Wolf JS, Matin SF, Huang W, Shalhav A, Eggener SE. Impact of warm versus cold ischemia on renal function following nephron-sparing surgery. J Urol 183(4):Supplement,, e319, 2010.
62. Abel EJ, Culp S, Tannir N, Matin SF, Jonasch E, Wood CG. Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma?. J Urol 183(4):Supplement, e641-e642, 2010.
63. Siefker-Radtke AO, Margulis V, Kamat AM, Grossman HB, Wood CG, Millikan RE, Dinney CP, Matin SF. Evidence for neoadjuvant chemotherapy for high-grade upper-tract urothelial cancer: A retrospective review from the M.D. Anderson Cancer Center. J Clin Oncol:282SA, 2010.
64. Parker PA, Latini DM, Ward JF, Pettaway C, Pisters LL, Matin SF, Frank SJ, Brown V, Kuban D, Logothetis C, Kim J, Davis JW. Association between uncertainty, anxiety, and quality of life in men with prostate cancer on active surveillance. Annals of Behavioral Medicine 37 (Supp)(37), 2009.
65. Svatek RS, Fisher MB, Matin SF, Kamat A, Dinney CP. BMI and age are independent predictors of postoperative ileus following radical cystectomy with pelvic lymphadenectomy. J Urol 181(4):126-127, 2009.
66. Chan AA, Caicedo J, Munsell MF, Matin SF. Intraoperative visual assessment as a predictor of renal function after open and laparoscopic partial nephrectomy. J Urol 181(4):251, 2009.
67. Abel EJ, Culp SH, Meissner M, Stamatakis L, Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Risk factors for disease progression in patients with localized (PT1, PT2) renal cell carcinoma (RCC) following surgical therapy. J Urol 181(4):357, 2009.
68. Margulis V, McDonald M, Matin SF, Tamboli P, Swanson DA, Wood CG. Predictors of oncologic outcome after resection of locally recurrent renal cell carcinoma. J Urol 181(4):496, 2009.
69. Culp SH, Abel EJ, Margulis V, Bill KL, Tamboli P, Jonasch E, Matin SF, Swanson DA, Tannir NM, Wood CG. Identifying patients with metastatic renal cell carcinoma who will not benefit from cytoreductive nephrectomy. J Urol 181(4):498, 2009.
70. Margulis V, Kattan MW, Matin SF, Tamboli P, Jonasch E, Tannir NM, Swanson DA, Wood CG. Prognostic nomograms for prediction of survival before or after cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 181(4):499, 2009.
71. Goh A, Matin SF. Laparoscopic partial nephrectomy for tumors near the renal hilum: a technique for preemptive anatomic dissction and vascular control. J Endourology 23(1):A354, 2009.
72. Matin SF, McCutcheon I, Gombos DS, Waguespack DS, Wen S, Smith LA, Zhang DW, Jonasch E, Davis D, Bouchillon K, Smith L, Fuller G. Treatment of VHL with sunitinib: clinical observations and transltional studies. J Clinical Oncol 27(supp):e22047, 2009.
73. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Insight into the natural history of surgically managed papillary renal cell carcinoma based on analysis of clinicopathologic predictors of oncologic outcome. JCO 26, 2008.
74. Fisher MB, Matin SF, Hegarty PK, McGinniss JE, Kamat AM, Grossman HB, Margulis V, Dinney CP. Cardiac history and risk of post-cystectomy cardiac complications. JCO 26, 2008.
75. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin SF, Jonasch E.. Von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. Journal of Clinical Oncology 25(18S), 2007.
76. Matin SF, Wood CG, Tu SM, Tannir NM, Jonasch E. Laparoscopic salvage nephrectomy after targeted neoadjuvant therapy for metastatic renal cell carcinoma: Initial results. J Urol 177(4):1103, 2007.
77. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Matin SF, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the presence of nonconventional histology. J Urol 177(4):1109, 2007.
78. Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Prognostic features of pathologic stage t3 renal cell carcinoma: Proposal for revision of current primary tumor classification. J Urol 177(4):901, 2007.
79. Matin SF, Jonasch E. Targeting von hippel-lindau syndrome: A single arm Phase II trial of Sunitinib Malate in patients undergoing surveillance of VHL-related lesions. J Urol 177(4):914, 2007.
80. Ponsky L, Cherullo E, Moinzadeh A, Kaouk J, Desai M, Gill I, George H, Frank I, Finelli A, Chen D, Fuchs G, Ng C, Matin SF, Singh D. The Hem-O-Lok Clip is safe for laparoscopic nephrectomies: A multi-institutional review. World Congress of Endourology & SWL MP02-8:60, 2007.
81. Matin SF, Tinkey P, Borne A, Stephens C, Scherz A, Swanson D. A pilot trial of vascular-targeted photodynamic therapy in renal tissue. World Congress of Endourology & SWL MP13-18:96, 2007.
82. Disick GIS, Kesler SS, Matin SF, Munver R. Clipless laparoscopic adrenalectomy: A feasible and reproducible technique for extirpative adrenal surgery. World Congress of Endourology & SWL MP16-18:114, 2007.
83. Patel H, Davis JW, Pisters LL, Matin SF. Retrospective comparison of initial operative times for RALP from three different urology practices in a major academic oncologic institution. World Congress of Endourology & SWL MP24-25:155, 2007.
84. Matin SF, Booth J, Ahrar K, Tamboli P, Wood CG. Contemporary strategies for managing nonhereditary synchronous bilateral renal tumors and the impact of minimally invasive, nephron-sparing techniques. World Congress of Endourology & SWL MP39-22:209, 2007.
85. Jonasch E, Tsavachidou D, Wood CG, Tamboli P, Tu S, Thomas C, Do KA, Matin SF, McDonnell T, Tannir N. Presurgical treatment of metastatic renal cell carcinoma patients with bevacizumab and erlotinib: Preliminary efficacy and biomaker data. EJC Supplements 4(12):80, 2006.
86. Sanchez-Ortiz R, Tamboli P, Lozano ML, Matin SF, Wood CG. Adjuvant thalidomide improves disease specific survival for patients with renal cell carcinoma at high risk for relapse following surgery. JCO 24(18):14586, 2006.
87. Kassouf W, Sanchez-Ortiz R, Tamboli P, Matin SF, Swanson D. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the presence of nonconventional histology. JCO 24(18):14535, 2006.
88. Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RA, Uzzo RG, Haaga J, Resnick MI, Kaouk JH, Gill IS. Residual and recurrent disease following renal energy ablative therapy: Implications for management - A multi-institutional study. J Urol 175(4):709, 2006.
89. Brassell S, Sanchez-Ortiz RF, Matin SF, Swanson DA, Wood CG. Resection of nodal disease in patients with metastatic conventional renal cell carcinoma improves survival. J Urol 175(4):743, 2006.
90. Busby JE, Brown GA, Matin SF. Efficacy of lymphadenectomy during laparoscopic radical nephroureterectomy: Comparison to the open approach. J Urol 175(4):1068, 2006.
91. Munver R, Lombardo SA, Volfson IA, Nazmy M, Matin SF. Advances in the minimally invasive treatment of benign and malignant adrenal lesions: Laparoscopic adrenalectomy using a novel vessel-sealing system - A combined experience. J Urol 175(4):1078, 2006.
92. Matin SF. Accessory pudendal arteries: Recognition and preservation during laparoscopic radical prostatectomy. J Endourol 20(1):V11-1, 2006.
93. Busby JE, Brown GA, Matin SF. Efficacy of lymphadenectomy during laparoscopic radical nephroureterectomy: comparison to the open approach and justification to perform. J Endourol 20(1):VP7-18, 2006.
94. Matin SF, Wood CG, Tu SM, Tannir N, Jonasch E. Laparoscopic salvage nephrectomy after targeted neoadjuvant therapy for metastatic renal cell carcinoma: Initial results. J Endourol 20(1):MP20-14, 2006.
95. Matin SF, Swisher SG, Vaporcyian AA. Expanding experience with laparoscopic-assisted radical nephrectomy and vena caval tumor thrombectomy. J Endourol 20(1):MP16-16, 2006.
96. Matin SF, Ahrar K, Wood CG, Jonasch E. How often is minimally-invasive therapy indicated for patients with VHL? Results from a VHL clinical care center. J Endourol 20(1):VP12-16, 2006.
97. Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RA, Uzzo RG, Haaga J, Resnick MI, Kaouk J, Gill IS. Residual and recurrent disease following renal energy-ablative therapy: Implications for management - A multi-institutional study. J Endourol 20(1):VP2-17, 2006.
98. Parker PA, Matin SF, Rosser CJ, Pisters LL. Prospective quality of life evaluation in patients undergoing laparoscopic and open renal surgery for renal cell carcinoma. J Endourol 20(1):VP4-7, 2006.
99. Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CPN, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treatment of upper urinary-tract transitional cell carcinoma: Time to change the treatment paradigm and not just the surgical approach. J Endourol 20(1):MP10-13, 2006.
100. Brown GA, Ramirez PT, Westney OL, Matin SF. Vaginal extraction of the intact specimen during laparoscopic extirpative renal surgery and concomitant pelvic surgery: An ideal indication. J Endourol 20(1):MP10-28, 2006.
101. Brown GA, Busby EJ, Matin SF, Dinney CPN, Grossman HB, Pettaway CA, Munsell MF, Czerniak B, Kamat AM. Ability of clinical grade to predict pathologic stage of disease in upper urinary tract transitional cell carcinoma. J Endourol 20(1):MP3-08, 2006.
102. Munver R, Volfson IA, Kesler S, Matin SF. Laparoscopic adrenalectomy for benign and malignant adrenal lesions using a novel vessel-sealing system: A combined experience. J Endourol 20(1):MP15-17, 2006.
103. Bochner BH, Uzzo RG, Sokoloff M, Pisters LL, Matin SF, Sanda MG, Arbor A, Colberg J, Wood CG, Konety BR, Penson DF. Current Status of Clinical Trials in Urothelial Cancers: A Summary from the ACOSOG GU Working Group. J Urol 173(4):1327, 2005.
104. Jacobsohn K, Ahrar K, Brown G, Wood CG, Matin SF. Is Radiofrequency Ablation Safe for Solitary Kidneys?. J Endourol 17(1):911, 2005.
105. Jacobsohn K, Ahrar K, Wood CG, Matin SF. Minimally Invasive Ablative Therapy For Small Renal Tumors: The MD Anderson Experience. J Endourol 17(1):912, 2005.
106. Matin SF. Recognition and Preservation of Accessory Pudendal Arteries During Laparoscopic Radical Prostatectomy. J Endourol 17(1):594, 2005.
107. Matin SF, Brown G. Laparoscopic Partial Nephrectomy: Factors Associated With Improved Outcomes. J Endourol 17(1):727, 2005.
108. Matin SF, Madsen L, Wood CG. Laparoscopic Cytoreductive Radical Nephrectomy: The M. D. Anderson Cancer Center Experience. J Urol 173(4):975, 2005.
109. Steinberg JR, Matin SF, Cohen DD, Zagone R, Wood CG. Evaluation Of The Intact Specimen In Patients Who Undergo Laparoscopic Radical Nephrectomy For Clinically Localized Renal Cell Carcinoma Identifies A Subset Of Patients At Increased Risk For Recurrence. J Urol 173(4):1176, 2005.
110. Wood CG, Cohen D, Steinberg J, Matin SF. Evaluation Of The Intact Specimen In Patients Who Undergo Laparoscopic Radical Nephrectomy For Clinically Localized Renal Cell Carcinoma Identifies A Subset Of Patients At Increased Risk For Recurrence. J Endourol 17(1):907, 2005.
111. Wood CG, Matin SF. Laparoscopic Cytoreductive Radical Nephrectomy: The M. D. Anderson Cancer Center Experience. J Endourol 17(1):559, 2005.
112. Goel MC, Matin SF, Derweesh IH, Streem SB, Levine H, Novick AC. Partial nephrectomy for renal urothelial tumor: insight into technique and results. J Urol 171(4):20, 2004.
113. Kuang W, Shin P, Matin SF, Thomas AJ. Robotic-assisted vasovasostomy: a pilot study. J Urol 171(4):V1472, 2004.
114. Gill IS, Matin SF, Desai MM, Steinberg A, Kaouk JH, Mascha E, Thorton J, Strzempkowski B, Sherief M, Novick A. Laparoscopic and open partial nephrectomy in 200 cases. J Urol 169(4):84, 2003.
115. Matin SF, Gill IS, Worley S, Novick AC. Outcome of laparoscopic radical nephrectomy and open partial nephrectomy for the sporadic (<4 cm) renal tumor with a normal contra-lateral kidney. J Urol 169(4):669, 2003.
116. Abreu SC, Gill IS, Kaouk J, Matin SF. Laparoscopic bilateral partial adrenalectomy for pheochromocytoma. J Urol 169(4):V73, 2003.
117. Mihir D, Abreau SC, Ramani A, Kaouk JH, Matin SF, Steinberg AP, Novick A, Gill IS. Advanced laparoscopic partial nephrectomy for renal tumors. J Urol 169(4):V425, 2003.
118. Steinberg AP, Lin CH, Matin SF, Desai M, Ng C, Kaouk J, Novick AC, Gill IS. Impact of tumor size on laparoscopic partial nephrectomy: Analysis of 163 patients. J Urol 169(4):671, 2003.
119. Ng CS, Abreu SC, Steinberg AP, Desai MM, Molina W, Matin SF, Kaouk J, Gill IS. Laparoscopic management of intra-parenchymal renal artery aneurysm. J Urol 169(4):V1875, 2003.
120. Kudo D, Matin SF, Steinberg A, Hobart M, Sung GT, Tannenbaum C, Novick AC, Finke JH, Gill IS. Renal cryotherapy of orthotopic RCC in an in-vivo murine model: feasibility, immunohistochemistry, and cytokine expression. J Urol 167(4):496, 2002.
121. Steinberg AP, Matin SF, Desai M, Kaouk J, Novick AC, Gill IS. Effect of tumor size on laparoscopic partial nephrectomy. J Endourol 16(1):P28-4, 2002.
122. Steinberg AP, Strzempkowski B, Kaouk J, Abreu SC, Ramani A, Farouk A, Matin SF, Sung GT, Novick AC, Gill IS. 3-Year and Greater Follow Up of Laparoscopic Renal Cryoablation. J Endourol 167(4):667, 2002.
123. Abreu SC, Gill IS, Kaouk JH, Matin SF, Meraney AM, Farouk A, Steinberg A, Desai M, Zippe C, Sung GT. Laparoscopic radical prostatectomy: Comparison of transperitoneal vs. extraperitoneal approach. J Urol 164(4):76, 2002.
124. Gill IS, Strzempkowski B, Kaouk J, Matin SF, Desai M, Sung GT, Meraney A. Prospective randomized comparison: Transperitoneal vs. retroperitoneal laparoscopic radical nephrectomy. J Urol 167(4):78, 2002.
125. Desai M, Gill I, Goel M, Kaouk J, Matin SF, Farouk A, Abreu SC, Steinberg A, Sung GT. Laparoscopic uteterocystoplasty using balloon-expanded normal ureter: Chronic porcine study. J Urol 167(4):236, 2002.
126. Desai M, Gill I, Kaouk J, Matin SF, Sung GT, Novick A. Advanced laparoscopic partial nephrectomy with pelvi-calyceal suture repair. J Urol 167(4):663, 2002.
127. Gill IS, Sung GT, Kaouk J, Matin SF, Abreu SC, Farouk A, Desai MM. Extraperitoneal laparoscopic radical prostatectomy: Cleveland Clinic technique. J Urol 167(4):V723, 2002.
128. Farouk A, Gill I, Kaouk J, Meraney A, Desai M, Matin SF, Abreu SC, Zippe C, Strzempkowski B, Sung GT. Laparoscopic radical prostatectomies (LRP): Learning curve in the United States. J Urol 167(4):1552, 2002.
129. Hsu THS, Matin SF, Kaouk J, Farouk A, Strzempkowski B, Sung GT, Gill IS. Laparoscopic extraperitoneal radical prostatectomy: Toward the gold standard. J Endourol 15(1):4, 2001.
130. Hsu THS, Matin SF, Meraney A, Murphy D, Kaouk J, Sung GT, Strezempkowski B, Novick AC, Gill IS. Laparoscopic radical nephrectomy: clinical and pathological update. J Endourol 15(1):2, 2001.
131. Matin SF, Kudo D, Hobart M, Tannenbaum C, Novick AC, Finke J, Gill IS. Renal cryotherapy of orthotopic RCC in an in-vivo murine model: feasibility, immunohistochemistry, and cytokine expression. J Endourol 15(1):8, 2001.
132. Matin SF, Yost A, Streem SB. Extracorporeal shock-wave lithotripsy: a comparative analysis of electrohydraulic and electromagnetic units. J Endourol 15(1):7, 2001.
133. Bandyopadhyay S, Matin SF, Rackley R, Chandra P, Novick AC. Interferon-resistant transitional-cell carcinomas have defective transduction factors: a clinical basis for interferon combination therapy. J Urol 161(4):425, 1999.
134. Matin SF, Streem SB. Metabolic risk factors in patients with ureteropelvic junction obstruction and renal calculi. J Urol 161(4):965, 1999.
135. Gao JJ, Karam JA, Tannir NM, Campbell MT, Tidwell RS, Ahrar K, Rao P, Ng CS, Jonasch E, Matin SF, Zurita AJ, Shah AY, Shen Y, Blando JM, Vence LM, Basu S, Zhao H, Allison JP, Wood CG, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). 2019 ASCO Annual Meeting.
136. Geynisman DM, Kadow BT, Shuch BM, Boorjian SA, Matin SF, Rampersaud E, McClean D, Milestone BN, Plimack ER, Zibelman MR, Kutikov A, Smaldone MC, Chen D, Viterbo R, Joshi S, Greenberg RE, Malizzia L, McGowan T, Ross EA, Uzzo R. Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE). 2019 Genitourinary Cancers Symposium.
137. Hasanov E, Peterson CB, Matin SF, Wood CG, Sircar K, Tannir NM, Jonasch E. Hypoxia Signaling and Immune Infiltration in a Presurgical Trial of Sunitinib in Patients with Clear Cell Renal Cell Carcinoma (RCC). 2019 ASCO Annual Meeting.
138. Gao JJ, Siefker-Radtke AO, Navai N, Campbell MT, Tidwell RS, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Allison JP, Dinney CP, Sharma P. A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). 2019 ASCO Annual Meeting.

Book Chapters

1. Abdelsalam ME, Matin SF, Ahrar K. Chapter 101: Ablation of Renal Cell Carcinoma. In: Image-Guided Interventions. 3rd. Elsevier, 823, 2020.
2. Hubosky SG, Vikram R, Matin SF. Endoluminal Ultrasound for Upper Tract Urothelial Carcinoma. In: Urothelial Malignancies of the Upper Urinary Tract. Springer, 63-70, 2018.
3. Raman JD, Warrick JL, Redrow GP, Matin SF. Upper Urinary Tract Carcinoma In Situ. In: Urothelial Malignancies of the Upper Urinary Tract. Springer, 85-95, 2018.
4. Matin SF. Systemic Chemotherapy for Upper Tract Urothelial Cancer. In: Urothelial Malignancies of the Upper Urinary Tract. Springer, 315-321, 2018.
5. Jayaratna IS, Matin SF, Pettaway C. Robotic-Assisted Inguinal Lymphadenectomy: The University of Texas M.D. Anderson Cancer Center Approach. In: Atlas of Robotic Urologic Surgery. 2nd. Springer: Switzerland, 331-337, 2017.
6. Wagenheim GN, Matin SF. Management of the Distal Ureter for Nephroureterectomy. In: Glenn's Urologic Surgery. 8th. Wolters Kluwer, 185-193, 2016.
7. Margulis V, Karam JA, Matin SF, Wood CG. Benign Renal Tumors. In: Campbell-Walsh Urology. 11th. Elsevier, 2015.
8. Jarrett TW, Smith AK, Matin SF. Urothelial Tumors of the Upper Urinary Tract and Ureter. In: Campbell-Walsh Urology. 11th. Elsevier, 58, 1365, 2015.
9. Merrill MM, Matin SF. Bladder Cancer, Urothelial, Superficial Carcinoma in SITU (CIS) (NMIBC). In: The 5-Minute Urology Consult. 3rd. Wolters Kluwer Health: Philadelphia, 64-65, 2015.
10. Merrill MM, Matin SF. Hematuria, Gross and Microscopic, Adult. In: The 5-Minute Urology Consult. 3rd. Wolters Kluwer Health: Philadelphia, 174 - 175, 2015.
11. Faria EF, Machado RD, Matin SF. Cancer da prostata: cirurgia para o cancer localmente avancado. In: Urologia Brasil, 2014.
12. Husain FZ, Remzi M, Margulis V, Porten S, Matin SF. Conservative Management of Low-Risk UTUC. In: Springer: Upper Tract Urothelial Carcinoma, 119-130, 2014.
13. Matin SF, Palou J, Margulis V, Coleman J, Catto J, Remzi M, deReijke T, de la Rosette J, Zlotta A, Yossepowitch O, O'Brien T, Traxer O, Anderson K, Kapoor A. Management of Low-Risk Disease: Endoscopy, Topical Therapy, Kidney-Preserving Surgery, and Surveillance. In: Upper Tract Urothelial Carcinoma. Société Internationale d’Urologie (SIU), 2014.
14. Matin SF. Management of Small Renal Masses and Early-Stage Renal Cell Carcinoma. In: Renal Cell Carcinoma. Oxford University Press: Oxford, 47-54, 2014.
15. Matin SF, Ahrar K. Thermal Ablation. In: Renal Cell Carcinoma. Springer Science+Business Media: New York, 155-166, 2013.
16. Delacroix SE, Matin SF, Araujo J, Wood CG.. Kidney Cancer. In: 60 Years of Survical Outcomes at The University of Texas MD Anderson Cancer Center. Springer Science+Business Media: New York, 133-142, 2013.
17. Faria EE, Machado RD, Matin SF. Surgery for locally advanced prostate cancer. In: Urologia Brasil. Planmark: Sao Paulo, 825-835, 2013.
18. Kamran A, Matin SF, Wallace MJ. Thermal Ablation of Renal Cell Carcinoma. In: Image-Guided Interventions,. 2nd, 2013.
19. Sandler CM, Vikram R, Matin SF, Wood C, Jonasch E. Renal Tumors. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier Saunders: Philadelphia, 287-310, 2012.
20. Kundra V, Kuban D, Matin SF, Kim J. Prostate Cancer. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier Saunders: Philadelphia, 377-402, 2012.
21. Matin SF Ahrar K,. "Management of Localized RCC: Thermal Ablation", in Renal Cell Carcinoma. In: Renal Cell Carcinoma. Clinical Management: Springer Press, 2012.
22. Shaw CM, Matin SF, Ahrar K. Energy ablative techniques in renal cell carcinoma. In: Kidney Cancer: Principles and Practice. Springer: New York, 141-161, 2012.
23. Margulis V, Matin SF, Wood CG. Benign Renal Tumors. In: Campbell-Walsh Urology. 10. Elsevier Saunders: Philadelphia, 1492-1505, 2012.
24. Margulis V, Matin SF, Wood CG. Benign renal masses. In: Campbells Urology. 10th edition. Elsevier Press: Philadelphia, 1492-1505, 2011.
25. Ponsky L, Matin SF. Special Considerations in Laparoscopy. In: Complications of Urologic Surgery: Diagnosis and Prevention. 4. Elsevier: St. Louis, 2010.
26. Rogers CF, Petros FG, Matin SF. Renal Ischemia and approach to the renal hilum - Tips and Tricks. In: Robotic Surgery. 2nd edition. Springer Press: Warrington, 2010.
27. Matin SF. Laparoscopic renal ultrasonography. In: Contemporary Interventional Ultrasonography in Urology. Dekker Publishers: New York, 2009.
28. Matin SF, Ahrar K. Management of Small Renal Masses: Ablative Therapies. In: Renal Cell Carcinoma. BC Decker Inc: CT, 2009.
29. Matin SF, Scherz A. Current status of photodynamic therapy for renal tumors. In: Renal Cell Cancer: Diagnosis and Therapy. Springer: New York, 317-322, 2008.
30. Matin SF, Tamboli P, Wood CG. Renal Angiomyolipoma. In: Clinical Management of Renal Tumors. The Humana Press, Inc: New Jersey, 565-586, 2008.
31. Matin SF. Renal cell carcinoma: surgical and medical treatment. In: Interventional Oncology: Principles and Practice. Cambridge University Press: New York, 2008.
32. Matin SF. Management of laparoscopic associated pneumothorax. In: Top Tips in Laparoscopic Urology. Euromed Communications: Haslemere, Surrey, UK, 19, 2007.
33. Matin SF. Automatic liver retraction for right laparoscopic nephrectomy. In: Top Tips in Laparoscopic Urology. Euromed Communications: Haslemere, Surrey, UK, 43, 2007.
34. Jonasch E, Matin SF, Wood CG, Pagliaro LC. Renal Cell Carcinoma. In: The M. D. Anderson Manual of Clinical Oncology. The McGraw-Hill Companies, Inc: New York, 2006.
35. Matin SF. Laparoscopic Radical Nephroureterectomy: Current Status. In: The Textbook of Laparoscopic Urology. Informa Healthcare USA, Inc: New York, 2006.
36. Matin SF, Gill IS. Retroperitoneal Tumors. In: 5-Minute Urology Consult. Williams and Wilkins: Baltimore, 2000.
37. Delacroix S, Matin SF, Wood CG. Kidney Cancer. In: M.D. Anderson Survival Monograph.
38. Rogers CG, Matin SF. Renal Ischemia and Approach to the Renal Hilum in Robotic Partial Nephrectomy: Tips and Tricks. In: Robotic Surgery.

Books (edited and written)

1. A Joint SIU-ICUD International Consultation. Upper Tract Urothelial Carcinoma. Ed(s) Shariat SF, Matin SF, Stenzl A. Société Internationale d’Urologie (SIU), 2014.

Letters to the Editor

1. Matin SF, Coleman JA. Misclassification of Upper Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JAMA Oncol.
2. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Functional recovery after partial nephrectomy: Effects of volume loss and ischemic injury. Journal of Urology 188: 1048-1049, 2012.
3. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Functional recovery after partial nephrectomy: Effects of volume loss and ischemic injury. Journal of Urology 187: 1667-1673, 2012.
4. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies?. Ann Oncol 22: 1243, 2011.